Index RUT
P/E 12.49
EPS (ttm) 6.55
Insider Own 2.43%
Shs Outstand 69.86M
Perf Week 3.58%
Market Cap 5.67B
Forward P/E 11.35
EPS next Y 7.21
Insider Trans -
Shs Float 67.63M
Perf Month 21.43%
Income 460.53M
PEG 0.33
EPS next Q 1.82
Inst Own 97.90%
Short Float 6.62%
Perf Quarter 26.59%
Sales 1.37B
P/S 4.15
EPS this Y 13.41%
Inst Trans -1.05%
Short Ratio 5.11
Perf Half Y 16.83%
Book/sh 13.39
P/B 6.11
EPS next Y 2.02%
ROA 28.96%
Short Interest 4.48M
Perf Year -5.50%
Cash/sh 10.36
P/C 7.90
EPS next 5Y 37.73%
ROE 66.21%
52W Range 50.20 - 94.47
Perf YTD 31.98%
Dividend Est. -
P/FCF 20.38
EPS past 5Y 35.30%
ROI 29.48%
52W High -13.38%
Beta 0.55
Dividend TTM -
Quick Ratio 4.55
Sales past 5Y 36.54%
Gross Margin 64.46%
52W Low 63.01%
ATR (14) 2.38
Dividend Ex-Date -
Current Ratio 4.84
EPS Y/Y TTM 2647.54%
Oper. Margin 34.60%
RSI (14) 66.96
Volatility 2.57% 3.15%
Employees 834
Debt/Eq 0.65
Sales Y/Y TTM 32.98%
Profit Margin 33.72%
Recom 1.18
Target Price 104.90
Option/Short Yes / Yes
LT Debt/Eq 0.65
EPS Q/Q 4616.43%
Payout 0.00%
Rel Volume 0.94
Prev Close 80.52
Sales Surprise 5.93%
EPS Surprise 9.46%
Sales Q/Q 23.00%
Earnings May 02 BMO
Avg Volume 876.46K
Price 81.83
SMA20 4.21%
SMA50 19.52%
SMA200 25.55%
Trades
Volume 824,277
Change 1.63%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-18-23 Downgrade
William Blair
Outperform → Mkt Perform
Dec-04-23 Initiated
TD Cowen
Outperform
$100
Sep-29-23 Initiated
William Blair
Outperform
Mar-08-23 Initiated
JMP Securities
Mkt Outperform
$120
Nov-30-22 Initiated
SVB Leerink
Outperform
Oct-13-22 Initiated
Mizuho
Buy
$105
May-09-22 Initiated
B. Riley Securities
Buy
$91
Apr-13-22 Initiated
Truist
Buy
$77
Feb-01-21 Initiated
SVB Leerink
Outperform
$24
Jun-29-20 Resumed
Jefferies
Buy
$29
Aug-16-19 Upgrade
CJS Securities
Market Perform → Market Outperform
Nov-02-17 Upgrade
Wells Fargo
Market Perform → Outperform
Nov-08-16 Reiterated
RBC Capital Mkts
Outperform
$6 → $12
Sep-23-16 Resumed
Credit Suisse
Neutral
Feb-24-16 Reiterated
RBC Capital Mkts
Outperform
$9 → $6
Dec-11-15 Downgrade
Credit Suisse
Outperform → Neutral
Sep-30-15 Downgrade
Wells Fargo
Outperform → Market Perform
Jul-20-15 Initiated
Wells Fargo
Outperform
Jul-20-15 Initiated
Robert W. Baird
Outperform
$10
Jul-20-15 Initiated
RBC Capital Mkts
Outperform
$10
Show Previous Ratings
May-31-24 12:00PM
May-30-24 07:00PM
07:00PM
11:55AM
May-28-24 09:40AM
08:00AM
Loading…
08:00AM
May-27-24 12:45PM
09:55AM
May-24-24 09:45AM
May-20-24 09:00AM
May-15-24 04:30PM
07:00AM
May-07-24 09:00AM
May-03-24 12:36PM
12:24PM
09:31AM
Loading…
09:31AM
03:04AM
May-02-24 11:14AM
10:30AM
09:14AM
08:35AM
07:32AM
(Associated Press Finance)
07:00AM
Apr-30-24 02:39PM
Apr-26-24 05:50PM
01:12PM
Apr-25-24 10:01AM
Apr-24-24 06:00PM
09:00AM
Apr-23-24 09:45AM
09:40AM
Loading…
09:40AM
Apr-19-24 12:10PM
Apr-18-24 08:00AM
Apr-15-24 06:00PM
09:50AM
Apr-13-24 12:12PM
Apr-11-24 09:00AM
Apr-10-24 02:18PM
Apr-09-24 06:00PM
Apr-05-24 09:00AM
Apr-03-24 05:45PM
Mar-28-24 10:04AM
07:30AM
Mar-26-24 05:45PM
Mar-25-24 09:00AM
Mar-22-24 09:30AM
Mar-20-24 05:45PM
Mar-14-24 05:45PM
09:50AM
Mar-13-24 04:30PM
Mar-12-24 09:00AM
Mar-11-24 07:01PM
Mar-08-24 05:45PM
03:00AM
Mar-07-24 09:40AM
Mar-06-24 09:55AM
09:30AM
Mar-05-24 10:15AM
08:30AM
08:00AM
Mar-04-24 08:30AM
Feb-28-24 08:30AM
Feb-27-24 09:00AM
Feb-26-24 11:00AM
08:30AM
Feb-23-24 11:00AM
10:48AM
09:30AM
Feb-22-24 09:30AM
08:30AM
08:12AM
07:33AM
(Associated Press Finance)
07:00AM
03:55AM
Feb-19-24 09:55AM
09:30AM
08:30AM
Feb-16-24 05:45PM
Feb-15-24 10:00AM
Feb-13-24 01:36PM
08:30AM
Feb-08-24 05:45PM
08:00AM
Feb-06-24 09:00AM
Feb-02-24 05:45PM
Jan-26-24 05:45PM
Jan-23-24 12:10PM
09:00AM
07:45AM
Jan-18-24 05:45PM
Jan-12-24 05:45PM
09:37AM
09:23AM
Jan-11-24 08:00AM
Jan-10-24 09:00AM
Jan-09-24 08:00AM
08:00AM
07:55AM
Jan-08-24 09:51AM
Jan-05-24 05:45PM
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Maeusli Heinz Christoph Director May 28 '24 Option Exercise 16.17 17,481 282,668 49,032 May 30 04:34 PM Maeusli Heinz Christoph Director May 28 '24 Sale 79.19 18,373 1,454,989 23,340 May 30 04:34 PM McHugh Julie Director May 28 '24 Sale 78.50 2,500 196,250 28,617 May 30 04:32 PM Sabens Andrea Chief Accounting Officer May 13 '24 Sale 76.89 341 26,219 62,898 May 15 05:09 PM Sabens Andrea Chief Accounting Officer Apr 15 '24 Sale 61.24 341 20,883 63,239 Apr 17 04:30 PM Marshall Robert J. Jr. CFO and Treasurer Mar 15 '24 Sale 60.00 20,000 1,200,000 113,749 Mar 19 04:30 PM Sabens Andrea Chief Accounting Officer Mar 13 '24 Sale 60.48 341 20,624 63,204 Mar 15 04:30 PM Blanchfield Paul President Mar 07 '24 Sale 61.96 18,023 1,116,705 103,357 Mar 11 04:30 PM LENO SAM R Director Mar 06 '24 Option Exercise 16.30 2,045 33,334 59,982 Mar 07 04:30 PM Lantheus Alpha Therapy, LLC 10% Owner Mar 06 '24 Buy 0.95 60,431,039 57,409,487 116,773,394 Mar 08 11:24 AM LENO SAM R Director Mar 06 '24 Sale 63.50 2,045 129,857 57,937 Mar 07 04:30 PM LENO SAM R Director Mar 05 '24 Option Exercise 16.30 2,045 33,334 59,982 Mar 07 04:30 PM LENO SAM R Director Mar 05 '24 Sale 64.62 2,045 132,148 57,937 Mar 07 04:30 PM LENO SAM R Director Mar 04 '24 Option Exercise 19.85 22,389 444,499 80,326 Mar 06 05:15 PM Heino Mary Anne Director Mar 04 '24 Sale 65.31 93,863 6,129,889 251,643 Mar 05 08:28 PM LENO SAM R Director Mar 04 '24 Sale 65.42 22,389 1,464,749 57,937 Mar 06 05:15 PM Sabens Andrea Chief Accounting Officer Feb 13 '24 Sale 55.31 341 18,861 58,403 Feb 15 04:30 PM Sabens Andrea Chief Accounting Officer Jan 16 '24 Sale 56.01 341 19,099 58,744 Jan 18 04:30 PM Marshall Robert J. Jr. CFO and Treasurer Dec 15 '23 Sale 78.24 10,000 782,400 103,170 Dec 19 05:00 PM Sabens Andrea Chief Accounting Officer Dec 13 '23 Sale 75.62 341 25,786 59,085 Dec 15 04:30 PM Blanchfield Paul President Nov 16 '23 Sale 67.96 1,500 101,940 88,651 Nov 20 04:30 PM Heino Mary Anne CEO Nov 13 '23 Sale 63.72 11,780 750,611 317,687 Nov 15 04:32 PM Sabens Andrea Chief Accounting Officer Nov 13 '23 Sale 63.57 341 21,677 59,426 Nov 15 04:30 PM Niedzwiecki Daniel See Remarks Sep 15 '23 Option Exercise 17.79 2,846 50,630 69,141 Sep 19 04:30 PM Niedzwiecki Daniel See Remarks Sep 15 '23 Sale 66.43 2,846 189,060 66,295 Sep 19 04:30 PM Blanchfield Paul President Aug 21 '23 Sale 66.10 408 26,969 90,067 Aug 23 04:30 PM Blanchfield Paul President Aug 18 '23 Sale 65.19 1,500 97,785 90,475 Aug 22 04:30 PM Marshall Robert J. Jr. CFO and Treasurer Aug 15 '23 Sale 68.52 10,000 685,200 108,298 Aug 17 04:30 PM Heino Mary Anne CEO Aug 11 '23 Sale 68.58 10,950 750,981 329,467 Aug 15 05:35 PM Niedzwiecki Daniel See Remarks Aug 11 '23 Sale 67.93 4,297 291,895 66,295 Aug 15 04:54 PM Sabens Andrea Chief Accounting Officer Jul 19 '23 Sale 90.87 1,752 159,209 59,767 Jul 21 04:30 PM Baylor-Henry Minnie Director Jun 02 '23 Sale 86.22 6 517 16 Oct 13 05:03 PM
Index RUT
P/E 1826.39
EPS (ttm) 0.01
Insider Own 0.19%
Shs Outstand 216.25M
Perf Week -1.13%
Market Cap 2.85B
Forward P/E 876.67
EPS next Y 0.01
Insider Trans 14.78%
Shs Float 216.21M
Perf Month 7.35%
Income 1.57M
PEG 182.64
EPS next Q -0.01
Inst Own 110.95%
Short Float 9.05%
Perf Quarter -23.50%
Sales 929.24M
P/S 3.07
EPS this Y 70.83%
Inst Trans 88.57%
Short Ratio 9.54
Perf Half Y -22.42%
Book/sh 14.52
P/B 0.91
EPS next Y 142.86%
ROA 0.03%
Short Interest 19.57M
Perf Year -24.81%
Cash/sh 0.78
P/C 16.91
EPS next 5Y 10.00%
ROE 0.05%
52W Range 11.46 - 24.09
Perf YTD -34.61%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI 0.04%
52W High -45.42%
Beta 1.19
Dividend TTM -
Quick Ratio 2.66
Sales past 5Y 17.12%
Gross Margin 50.83%
52W Low 14.75%
ATR (14) 0.48
Dividend Ex-Date -
Current Ratio 3.82
EPS Y/Y TTM -76.68%
Oper. Margin 8.09%
RSI (14) 50.54
Volatility 3.16% 3.44%
Employees 2640
Debt/Eq 0.28
Sales Y/Y TTM 28.93%
Profit Margin 0.17%
Recom 2.00
Target Price 17.00
Option/Short Yes / Yes
LT Debt/Eq 0.28
EPS Q/Q -124.60%
Payout -
Rel Volume 0.85
Prev Close 13.19
Sales Surprise -0.35%
EPS Surprise -166.67%
Sales Q/Q 4.84%
Earnings Apr 09 BMO
Avg Volume 2.05M
Price 13.15
SMA20 1.54%
SMA50 -0.63%
SMA200 -21.31%
Trades
Volume 1,748,242
Change -0.30%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-16-23 Initiated
Wells Fargo
Overweight
$22
Nov-22-22 Upgrade
William Blair
Mkt Perform → Outperform
Jul-12-22 Initiated
Piper Sandler
Neutral
$25
May-23-19 Initiated
Guggenheim
Neutral
Dec-05-17 Resumed
ROTH Capital
Neutral
$82
Jul-14-17 Initiated
CL King
Neutral
Jun-05-14 Initiated
William Blair
Mkt Perform
Mar-31-11 Upgrade
Hilliard Lyons
Underperform → Neutral
Sep-25-09 Reiterated
Roth Capital
Buy
$33 → $36
Jul-22-09 Reiterated
Roth Capital
Buy
$29 → $33
Mar-20-09 Reiterated
Roth Capital
Buy
$32 → $28
Jan-07-09 Reiterated
Roth Capital
Buy
$33 → $32
Sep-25-08 Reiterated
Roth Capital
Buy
$30 → $33
Jan-04-08 Reiterated
Roth Capital
Buy
$28 → $30
Sep-28-07 Reiterated
Roth Capital
Buy
$23.33 → $28
Jul-25-07 Reiterated
Roth Capital
Buy
$33 → $35
Jul-09-07 Reiterated
Roth Capital
Buy
$27 → $33
May-08-07 Initiated
Susquehanna Financial
Positive
Show Previous Ratings
May-30-24 04:30PM
May-28-24 07:13AM
May-15-24 11:56AM
May-10-24 11:38AM
May-09-24 11:30AM
08:45AM
Loading…
May-08-24 08:45AM
May-07-24 08:45AM
May-01-24 08:45AM
Apr-30-24 08:45AM
Apr-28-24 06:32PM
Apr-24-24 09:31AM
Apr-22-24 10:44AM
Apr-18-24 08:45AM
Apr-17-24 03:00PM
Apr-11-24 01:48PM
08:45AM
Loading…
08:45AM
03:24AM
Apr-10-24 09:40AM
08:06AM
03:01AM
Apr-09-24 09:54PM
(Thomson Reuters StreetEvents) -9.32%
05:30PM
12:40PM
12:38PM
(Associated Press Finance)
11:52AM
11:39AM
08:11AM
08:10AM
07:16AM
07:07AM
(Associated Press Finance)
07:00AM
Loading…
07:00AM
Apr-04-24 09:15AM
Mar-19-24 04:30PM
Mar-07-24 07:29AM
Feb-08-24 11:30AM
Feb-06-24 04:30PM
Jan-30-24 01:51PM
Jan-17-24 08:45AM
Jan-15-24 08:45AM
Jan-11-24 08:16AM
Jan-10-24 12:52PM
Jan-09-24 10:09PM
(Thomson Reuters StreetEvents) -8.37%
05:30PM
04:03PM
12:51PM
12:12PM
(Associated Press Finance)
07:07AM
(Associated Press Finance)
07:00AM
Dec-21-23 08:45AM
Dec-19-23 08:45AM
Dec-15-23 12:13PM
08:55AM
Dec-14-23 08:45AM
Dec-06-23 08:16AM
Dec-05-23 08:45AM
Dec-01-23 11:01AM
Nov-30-23 08:45AM
04:10AM
Nov-21-23 08:45AM
Nov-17-23 11:23AM
Nov-09-23 11:30AM
Oct-26-23 01:03PM
Oct-11-23 11:01PM
12:43PM
09:42AM
09:39AM
Oct-10-23 09:33PM
(Thomson Reuters StreetEvents) -5.31%
08:00PM
02:02PM
12:10PM
(Associated Press Finance)
11:41AM
09:35AM
08:15AM
07:24AM
07:10AM
07:00AM
Oct-04-23 11:29AM
Sep-27-23 09:12AM
Sep-26-23 08:45AM
Sep-08-23 09:35AM
Sep-07-23 03:49PM
11:51AM
Sep-06-23 06:01AM
Sep-04-23 09:00AM
Sep-01-23 08:45AM
Aug-31-23 08:45AM
07:06AM
Aug-30-23 08:45AM
Aug-24-23 04:00PM
Aug-17-23 09:09AM
Aug-16-23 05:05PM
(The Wall Street Journal)
Aug-15-23 08:45AM
Aug-11-23 07:03AM
Aug-08-23 08:45AM
Jul-29-23 08:10AM
Jul-28-23 08:14AM
Jul-27-23 08:35AM
07:39AM
07:00AM
Jul-20-23 10:02AM
Neogen Corp. engages in the development, manufacture, and marketing of food and animal safety products. It operates through the Food Safety and Animal Safety segments. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ADENT JOHN EDWARD CEO Apr 25 '24 Option Exercise 11.96 2,113 25,271 171,979 Apr 26 12:50 PM Jones Douglas Edward Chief Operating Officer Apr 25 '24 Option Exercise 11.96 845 10,106 46,976 Apr 26 12:38 PM Rocklin Amy M Chief Legal Officer Apr 25 '24 Option Exercise 11.96 563 6,733 10,456 Apr 26 09:48 AM Jones Douglas Edward Chief Operating Officer Apr 17 '24 Buy 12.36 10,000 123,590 46,131 Apr 17 12:04 PM BOREL JAMES C Director Apr 11 '24 Buy 13.06 7,500 97,986 21,392 Apr 11 11:40 AM ADENT JOHN EDWARD CEO Apr 10 '24 Buy 12.36 23,000 284,190 152,389 Apr 10 02:25 PM Naemura David H. CFO Apr 10 '24 Buy 12.51 12,500 156,321 30,040 Apr 10 04:18 PM BOEHM WILLIAM T Director Nov 03 '23 Buy 16.05 2,000 32,110 26,509 Nov 03 01:59 PM Jones Douglas Edward Chief Operating Officer Oct 25 '23 Buy 15.17 10,000 151,727 36,131 Oct 26 08:01 AM Lilly Jason Warren Vice President Oct 13 '23 Sale 15.10 351 5,300 26,744 Oct 17 10:06 AM Tobin James P Director Oct 12 '23 Buy 15.19 3,000 45,567 20,392 Oct 12 04:01 PM Naemura David H. CFO Oct 11 '23 Buy 15.03 10,000 150,333 10,000 Oct 11 04:21 PM BOEHM WILLIAM T Director Oct 11 '23 Sale 15.61 2,591 40,456 24,509 Oct 12 11:54 AM Lilly Jason Warren Vice President Oct 11 '23 Sale 15.69 1,917 30,087 25,944 Oct 12 11:25 AM BOEHM WILLIAM T Director Aug 18 '23 Option Exercise 15.62 1,500 23,430 26,009 Aug 22 10:57 AM BOEHM WILLIAM T Director Aug 18 '23 Sale 22.59 1,500 33,891 24,509 Aug 22 10:57 AM
Index -
P/E -
EPS (ttm) -25.27
Insider Own 14.23%
Shs Outstand 13.36M
Perf Week -3.33%
Market Cap 36.61M
Forward P/E -
EPS next Y -1.70
Insider Trans 129.25%
Shs Float 11.46M
Perf Month 7.45%
Income -40.86M
PEG -
EPS next Q -0.50
Inst Own 52.57%
Short Float 3.05%
Perf Quarter -8.67%
Sales 1.38M
P/S 26.53
EPS this Y 36.89%
Inst Trans -23.99%
Short Ratio 5.62
Perf Half Y -27.89%
Book/sh 1.40
P/B 1.96
EPS next Y 28.17%
ROA -51.95%
Short Interest 0.35M
Perf Year -35.89%
Cash/sh 0.42
P/C 6.56
EPS next 5Y -
ROE -132.29%
52W Range 2.08 - 4.86
Perf YTD 9.60%
Dividend Est. -
P/FCF -
EPS past 5Y 14.72%
ROI -210.26%
52W High -43.67%
Beta 0.82
Dividend TTM -
Quick Ratio 0.78
Sales past 5Y 16.25%
Gross Margin -60.27%
52W Low 31.73%
ATR (14) 0.19
Dividend Ex-Date -
Current Ratio 0.78
EPS Y/Y TTM -92.98%
Oper. Margin -1580.32%
RSI (14) 47.86
Volatility 6.94% 7.24%
Employees 46
Debt/Eq 0.20
Sales Y/Y TTM -
Profit Margin -2956.66%
Recom 1.67
Target Price 4.42
Option/Short No / Yes
LT Debt/Eq 0.15
EPS Q/Q -380.86%
Payout -
Rel Volume 0.65
Prev Close 2.65
Sales Surprise -49.71%
EPS Surprise 7.81%
Sales Q/Q -40.74%
Earnings May 15 AMC
Avg Volume 62.18K
Price 2.74
SMA20 -2.90%
SMA50 -1.77%
SMA200 -10.38%
Trades
Volume 40,524
Change 3.40%
Date
Action
Analyst
Rating Change
Price Target Change
May-24-22 Downgrade
Stephens
Overweight → Equal-Weight
Mar-14-22 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Jan-07-22 Initiated
Stephens
Overweight
$3.10
Jan-06-22 Resumed
Piper Sandler
Overweight
$3.10
Mar-17-21 Resumed
Needham
Buy
$8
Jan-07-21 Upgrade
The Benchmark Company
Speculative Buy → Buy
$6
Dec-16-20 Upgrade
Piper Sandler
Neutral → Overweight
$2 → $4
Nov-30-20 Initiated
BTIG Research
Buy
$5
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$5
Jul-30-20 Reiterated
The Benchmark Company
Speculative Buy
$7 → $6
Jul-01-20 Downgrade
Piper Sandler
Overweight → Neutral
Jun-30-20 Downgrade
Chardan Capital Markets
Buy → Neutral
$2
Jun-02-20 Initiated
Needham
Buy
$4
Feb-13-19 Initiated
Piper Jaffray
Overweight
$6
Jan-29-19 Upgrade
Janney
Neutral → Buy
Dec-19-18 Resumed
Lake Street
Buy
Show Previous Ratings
May-30-24 04:47PM
May-15-24 08:55PM
04:05PM
May-13-24 08:00AM
May-07-24 09:19AM
10:52AM
Loading…
Apr-12-24 10:52AM
06:00AM
Apr-11-24 09:46PM
05:30PM
Apr-09-24 04:05PM
Jan-16-24 08:00AM
Dec-06-23 08:00AM
Nov-09-23 08:27AM
07:00AM
Nov-03-23 08:30AM
08:00AM
Loading…
Sep-18-23 08:00AM
Sep-06-23 08:00AM
Aug-28-23 08:30AM
Aug-10-23 07:00AM
Aug-09-23 08:00AM
Aug-08-23 08:30AM
Aug-03-23 08:00AM
Jul-25-23 09:08AM
Jul-24-23 01:35PM
Jun-27-23 08:30AM
Jun-01-23 04:15PM
May-11-23 08:00AM
Apr-27-23 04:59PM
Apr-18-23 08:45AM
Apr-12-23 04:15PM
08:24AM
Loading…
Apr-07-23 08:24AM
Apr-03-23 08:00AM
Mar-31-23 05:00PM
Mar-29-23 04:01PM
Mar-15-23 04:01PM
Mar-02-23 09:00AM
Feb-22-23 08:00AM
Dec-16-22 08:19AM
08:00AM
Nov-30-22 06:05PM
06:00PM
Nov-10-22 04:30PM
Oct-27-22 04:01PM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-31-22 04:01PM
Aug-30-22 04:27PM
Aug-24-22 08:00AM
Aug-10-22 04:05PM
Aug-03-22 04:01PM
Aug-01-22 11:33AM
05:00AM
Jul-27-22 04:01PM
Jul-13-22 08:00AM
Jul-06-22 08:00AM
Jun-22-22 08:00AM
Jun-15-22 07:15AM
May-26-22 05:00PM
May-11-22 04:05PM
May-05-22 08:00AM
Apr-28-22 04:01PM
Apr-27-22 04:30PM
Apr-22-22 09:26AM
Apr-13-22 10:01PM
05:12PM
05:10PM
Apr-11-22 08:00AM
Mar-28-22 08:00AM
Mar-10-22 04:05PM
Mar-01-22 04:05PM
Feb-21-22 07:26AM
Feb-10-22 08:00AM
Jan-18-22 04:05PM
Jan-06-22 09:43AM
Jan-04-22 08:00AM
Dec-09-21 06:00PM
Dec-08-21 08:00AM
Dec-06-21 08:00AM
Dec-02-21 08:00AM
Nov-22-21 06:14AM
Nov-09-21 04:05PM
Nov-04-21 08:00AM
Nov-02-21 03:02PM
Oct-27-21 08:00AM
Oct-26-21 04:05PM
Oct-08-21 09:46AM
Oct-07-21 08:00AM
Sep-30-21 08:00AM
Sep-20-21 11:35AM
08:00AM
Sep-16-21 08:00AM
Sep-13-21 08:00AM
Sep-07-21 04:05PM
Aug-23-21 09:13AM
Aug-18-21 08:49AM
Aug-17-21 08:00AM
Aug-10-21 04:01PM
Aug-09-21 08:00AM
Aug-03-21 03:00PM
Jul-27-21 10:35AM
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BROADWOOD PARTNERS, L.P. 10% Owner Apr 11 '24 Buy 2.92 2,420,000 7,057,688 4,929,066 Apr 15 07:21 PM Arno Andrew Director Apr 11 '24 Buy 2.95 33,898 99,999 69,054 Apr 15 06:02 AM Riggs Josh CEO and President Apr 11 '24 Buy 2.95 3,390 10,000 3,505 Apr 15 06:04 AM KINGSLEY ALFRED D Director Jun 14 '23 Buy 0.21 30,000 6,447 469,111 Jun 15 08:13 PM
Index -
P/E -
EPS (ttm) -0.09
Insider Own 26.66%
Shs Outstand 674.14M
Perf Week -8.61%
Market Cap 930.31M
Forward P/E -
EPS next Y -0.11
Insider Trans 52.65%
Shs Float 494.45M
Perf Month -18.82%
Income -23.91M
PEG -
EPS next Q -0.02
Inst Own 34.07%
Short Float 3.09%
Perf Quarter 45.45%
Sales 8.84M
P/S 105.24
EPS this Y 42.02%
Inst Trans -1.05%
Short Ratio 2.69
Perf Half Y 452.00%
Book/sh 0.39
P/B 3.52
EPS next Y -9.90%
ROA -27.07%
Short Interest 15.26M
Perf Year 160.38%
Cash/sh 0.27
P/C 5.15
EPS next 5Y -
ROE -29.53%
52W Range 0.20 - 1.90
Perf YTD 243.28%
Dividend Est. -
P/FCF -
EPS past 5Y -7.69%
ROI -10.28%
52W High -27.56%
Beta 1.44
Dividend TTM -
Quick Ratio 12.98
Sales past 5Y -
Gross Margin 27.13%
52W Low 573.17%
ATR (14) 0.16
Dividend Ex-Date -
Current Ratio 12.98
EPS Y/Y TTM -45.00%
Oper. Margin -346.50%
RSI (14) 39.69
Volatility 13.14% 10.99%
Employees 119
Debt/Eq 0.01
Sales Y/Y TTM -19.63%
Profit Margin -270.46%
Recom 1.00
Target Price 2.22
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q -7.83%
Payout -
Rel Volume 2.75
Prev Close 1.32
Sales Surprise -11.88%
EPS Surprise 28.57%
Sales Q/Q -82.29%
Earnings May 15 BMO
Avg Volume 5.67M
Price 1.38
SMA20 -15.52%
SMA50 -9.70%
SMA200 84.93%
Trades
Volume 15,604,122
Change 4.55%
Date
Action
Analyst
Rating Change
Price Target Change
May-09-24 Initiated
Cantor Fitzgerald
Overweight
May-24-24 08:01AM
May-20-24 07:00AM
May-15-24 07:49AM
07:13AM
(Associated Press Finance)
07:00AM
07:00AM
Loading…
May-03-24 07:00AM
03:04AM
May-02-24 07:00AM
Apr-30-24 07:00AM
07:00AM
Apr-08-24 08:00AM
Mar-30-24 05:31AM
Mar-28-24 07:30AM
Mar-19-24 10:39AM
(The Wall Street Journal) +16.06%
Mar-18-24 08:00AM
08:00AM
Loading…
Mar-11-24 08:00AM
Mar-05-24 08:00AM
Mar-04-24 09:45AM
Feb-26-24 08:00AM
Feb-20-24 06:30AM
(The Wall Street Journal)
Feb-12-24 08:00AM
Feb-08-24 10:00AM
Feb-01-24 08:00AM
Jan-22-24 04:05PM
Jan-18-24 07:00AM
Jan-17-24 04:05PM
08:00AM
Jan-09-24 08:00AM
08:00AM
Jan-05-24 08:00AM
08:00AM
Loading…
Jan-02-24 08:00AM
Dec-12-23 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-27-23 08:00AM
Nov-16-23 08:00AM
Nov-14-23 04:25PM
Nov-08-23 08:00AM
Oct-16-23 08:00AM
Oct-10-23 08:00AM
Oct-05-23 04:05PM
Sep-12-23 08:00AM
Sep-11-23 08:00AM
Aug-30-23 08:17AM
Aug-28-23 08:00AM
Aug-11-23 09:15AM
08:11AM
08:05AM
08:00AM
Aug-09-23 08:05AM
Jun-27-23 08:00AM
Jun-21-23 08:00AM
Jun-16-23 08:00AM
Jun-08-23 08:00AM
May-28-23 06:36PM
May-24-23 08:10AM
May-16-23 05:02AM
May-15-23 08:22PM
05:35PM
04:49PM
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1998 and is headquartered in Seattle, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Williamson Robert F III Director May 29 '24 Buy 1.33 30,031 40,014 368,792 May 30 04:05 PM Austin Mark John VP Finance/Prin Fin&Acct Offic Apr 23 '24 Option Exercise 0.36 30,000 10,800 84,030 Apr 24 04:35 PM Lantheus Alpha Therapy, LLC 10% Owner Mar 06 '24 Buy 0.95 60,431,039 57,409,487 116,773,394 Mar 08 11:24 AM Williamson Robert F III Director Jan 30 '24 Buy 0.71 127,206 90,710 338,761 Feb 01 04:53 PM Williamson Robert F III Director Jan 29 '24 Buy 0.64 25,266 16,170 211,555 Jan 30 04:57 PM Williamson Robert F III Director Jan 26 '24 Buy 0.56 110,613 62,304 186,289 Jan 30 04:57 PM Williamson Robert F III Director Jan 25 '24 Buy 0.49 22,134 10,846 75,676 Jan 26 05:38 PM Puhlmann Markus Chief Medical Officer Jan 24 '24 Buy 0.50 280,000 139,888 1,375,425 Jan 26 05:40 PM Williamson Robert F III Director Jan 24 '24 Buy 0.49 29,862 14,632 53,542 Jan 26 05:38 PM Williamson Robert F III Director Dec 21 '23 Buy 0.33 3,663 1,203 3,663 Dec 26 05:00 PM Puhlmann Markus Chief Medical Officer Dec 19 '23 Buy 0.34 400,000 137,000 1,095,425 Dec 19 07:09 PM Williamson Robert F III Director Dec 19 '23 Buy 0.32 13,680 4,378 23,680 Dec 19 07:10 PM Hunt Jonathan Robert Chief Financial Officer Dec 18 '23 Buy 0.26 125,000 32,338 316,710 Dec 19 07:11 PM Puhlmann Markus Chief Medical Officer Dec 18 '23 Buy 0.26 60,419 15,461 695,425 Dec 19 07:09 PM Williamson Robert F III Director Dec 18 '23 Buy 0.26 10,000 2,600 10,000 Dec 19 07:10 PM Woods Lori A Director Dec 15 '23 Buy 0.27 152,962 41,284 1,519,738 Dec 18 04:16 PM Puhlmann Markus Chief Medical Officer Dec 15 '23 Buy 0.27 135,006 36,276 635,006 Dec 19 07:09 PM Woods Lori A Director Dec 14 '23 Buy 0.27 32,238 8,704 1,366,776 Dec 18 04:16 PM
Index NDX, S&P 500
P/E 48.15
EPS (ttm) 10.32
Insider Own 1.08%
Shs Outstand 83.03M
Perf Week -3.71%
Market Cap 41.04B
Forward P/E 39.42
EPS next Y 12.61
Insider Trans -7.47%
Shs Float 81.69M
Perf Month 6.18%
Income 866.57M
PEG 4.01
EPS next Q 2.89
Inst Own 90.29%
Short Float 2.07%
Perf Quarter -13.85%
Sales 3.72B
P/S 11.02
EPS this Y 10.00%
Inst Trans -0.23%
Short Ratio 3.71
Perf Half Y 6.47%
Book/sh 18.93
P/B 26.25
EPS next Y 13.91%
ROA 28.13%
Short Interest 1.69M
Perf Year 6.92%
Cash/sh 4.81
P/C 103.27
EPS next 5Y 12.00%
ROE 71.91%
52W Range 372.50 - 583.39
Perf YTD -10.47%
Dividend Est. -
P/FCF 51.51
EPS past 5Y 18.76%
ROI 37.78%
52W High -14.82%
Beta 1.34
Dividend TTM -
Quick Ratio 1.10
Sales past 5Y 10.69%
Gross Margin 60.08%
52W Low 33.41%
ATR (14) 12.53
Dividend Ex-Date -
Current Ratio 1.51
EPS Y/Y TTM 24.13%
Oper. Margin 29.90%
RSI (14) 43.53
Volatility 2.17% 2.42%
Employees 11000
Debt/Eq 0.68
Sales Y/Y TTM 8.57%
Profit Margin 23.26%
Recom 2.15
Target Price 579.96
Option/Short Yes / Yes
LT Debt/Eq 0.46
EPS Q/Q 10.06%
Payout 0.00%
Rel Volume 2.05
Prev Close 499.77
Sales Surprise -0.03%
EPS Surprise 3.60%
Sales Q/Q 7.10%
Earnings May 01 BMO
Avg Volume 455.43K
Price 496.95
SMA20 -2.31%
SMA50 -2.16%
SMA200 -0.81%
Trades
Volume 931,658
Change -0.56%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-24 Downgrade
Piper Sandler
Overweight → Neutral
$525
Dec-07-23 Initiated
Exane BNP Paribas
Outperform
$602
Dec-04-23 Upgrade
Cleveland Research
Neutral → Buy
Aug-02-23 Downgrade
Atlantic Equities
Overweight → Neutral
$610
Jul-25-22 Downgrade
Stifel
Buy → Hold
$415
Jul-21-22 Upgrade
Goldman
Neutral → Buy
$530 → $435
Jul-12-22 Initiated
Piper Sandler
Overweight
$440
May-05-22 Downgrade
BofA Securities
Buy → Neutral
$550 → $470
Feb-08-22 Initiated
Atlantic Equities
Overweight
$650
Nov-18-21 Initiated
Morgan Stanley
Overweight
Aug-05-21 Resumed
Credit Suisse
Outperform
$735
Jul-12-21 Downgrade
Guggenheim
Buy → Neutral
Feb-17-21 Initiated
Barclays
Overweight
$600
Sep-09-19 Initiated
Goldman
Neutral
$277
May-23-19 Initiated
Guggenheim
Buy
$276
Nov-02-18 Reiterated
BofA/Merrill
Buy
$275 → $235
May-07-18 Reiterated
Stifel
Buy
$215 → $225
Jan-16-18 Initiated
Piper Jaffray
Overweight
$200
Aug-23-17 Upgrade
BofA/Merrill
Neutral → Buy
Jul-28-17 Upgrade
CL King
Neutral → Buy
Show Previous Ratings
May-31-24 11:31AM
May-29-24 06:00AM
May-25-24 03:00PM
May-20-24 11:18AM
May-14-24 02:00PM
08:27AM
Loading…
08:27AM
May-13-24 02:25PM
May-04-24 07:38AM
May-02-24 02:22PM
02:17PM
10:31AM
10:30AM
10:20AM
09:46AM
09:23AM
03:08AM
Loading…
03:08AM
May-01-24 11:28PM
(Thomson Reuters StreetEvents) -5.02%
02:31PM
10:41AM
09:30AM
08:11AM
07:52AM
07:40AM
07:10AM
06:38AM
(Associated Press Finance)
06:30AM
Apr-30-24 10:02AM
Apr-28-24 06:32PM
Apr-26-24 09:15AM
Apr-24-24 12:01PM
07:56AM
Loading…
Apr-19-24 07:56AM
Apr-12-24 01:53PM
Apr-09-24 06:00PM
12:00PM
Apr-05-24 12:10PM
Apr-04-24 04:30PM
Apr-02-24 08:31AM
Mar-29-24 02:15AM
Mar-21-24 05:42AM
Mar-08-24 03:01AM
Mar-06-24 11:30AM
Mar-05-24 03:05AM
Feb-22-24 03:46AM
Feb-20-24 02:00PM
Feb-18-24 01:26PM
Feb-16-24 12:56PM
Feb-15-24 11:53AM
07:00AM
Feb-10-24 02:07AM
Feb-09-24 03:35PM
Feb-08-24 10:34AM
Feb-06-24 02:25PM
(Investor's Business Daily)
08:46AM
02:05AM
(Thomson Reuters StreetEvents)
Feb-05-24 10:31PM
(Morningstar Research) +8.53%
10:37AM
09:30AM
07:45AM
07:40AM
06:53AM
06:39AM
(Associated Press Finance)
06:30AM
Feb-02-24 08:46AM
Jan-31-24 09:15AM
07:29AM
Jan-30-24 12:10PM
Jan-29-24 11:58AM
Jan-25-24 07:18AM
Jan-23-24 03:30PM
Jan-19-24 07:14AM
Jan-15-24 11:33AM
Jan-12-24 07:05AM
07:00AM
Jan-11-24 09:48PM
Dec-18-23 07:40AM
05:19AM
Dec-09-23 01:05AM
Dec-07-23 09:16PM
04:15PM
Dec-06-23 03:25PM
(Investor's Business Daily)
Dec-04-23 08:12PM
(Morningstar Research) +7.05%
Dec-01-23 11:31AM
Nov-16-23 09:28AM
Nov-13-23 06:10AM
Nov-11-23 12:00PM
Nov-09-23 07:48AM
Nov-08-23 07:00AM
Nov-02-23 06:55PM
08:52AM
01:10AM
12:45AM
(Thomson Reuters StreetEvents)
Nov-01-23 10:00PM
02:52PM
09:53AM
09:28AM
08:46AM
06:40AM
(Associated Press Finance)
06:30AM
Oct-31-23 11:25AM
Oct-25-23 10:02AM
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Claflin Bruce L. Director May 17 '24 Sale 540.80 200 108,160 161 May 20 05:00 PM Kingsley Lawrence D Director May 06 '24 Option Exercise 0.00 339 0 8,883 May 08 07:02 PM SZOSTAK M ANNE Director May 06 '24 Option Exercise 0.00 257 0 257 May 08 07:02 PM Vandebroek Sophie V. Director May 06 '24 Option Exercise 0.00 257 0 1,473 May 08 07:02 PM COLLINS Asha Director May 06 '24 Option Exercise 0.00 257 0 779 May 08 07:01 PM ESSIG STUART Director May 06 '24 Option Exercise 0.00 257 0 1,974 May 08 07:01 PM AYERS JONATHAN W Director May 06 '24 Option Exercise 0.00 257 0 265,651 May 08 07:00 PM Britt Irene Chang Director May 06 '24 Option Exercise 0.00 208 0 208 May 08 07:00 PM POLEWACZYK JAMES F Executive Vice President Mar 06 '24 Option Exercise 422.45 8,104 3,423,547 18,815 Mar 07 05:00 PM POLEWACZYK JAMES F Executive Vice President Mar 06 '24 Sale 558.44 8,104 4,525,596 10,711 Mar 07 05:00 PM Vandebroek Sophie V. Director Mar 05 '24 Option Exercise 245.79 1,404 345,089 2,620 Mar 07 05:00 PM Vandebroek Sophie V. Director Mar 05 '24 Sale 562.98 1,404 790,427 1,216 Mar 07 05:00 PM MAZELSKY JONATHAN JAY President and CEO Feb 21 '24 Option Exercise 206.94 483 99,952 82,047 Feb 22 05:02 PM Underberg Sharon E. EVP, GC & Corporate Secretary Feb 16 '24 Option Exercise 206.94 483 99,952 5,595 Feb 20 05:01 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 15 '24 Option Exercise 206.94 483 99,952 30,835 Feb 20 05:00 PM Smith Martin Alexander Executive Vice President Feb 14 '24 Option Exercise 0.00 337 0 583 Feb 16 05:58 PM Schreck Michael Executive Vice President Feb 14 '24 Option Exercise 0.00 368 0 903 Feb 16 05:58 PM Johnson Michael Perkins EVP and CHRO Feb 14 '24 Option Exercise 0.00 176 0 243 Feb 16 05:56 PM Lane Michael Executive Vice President Feb 14 '24 Option Exercise 0.00 939 0 6,726 Feb 16 05:56 PM MAZELSKY JONATHAN JAY President and CEO Feb 14 '24 Option Exercise 0.00 4,156 0 83,403 Feb 16 05:56 PM Erickson Michael G Executive Vice President Feb 14 '24 Option Exercise 0.00 462 0 10,801 Feb 16 05:54 PM FENNELL GEORGE SVP, Chief Revenue Officer Feb 14 '24 Option Exercise 0.00 370 0 7,082 Feb 16 05:55 PM Hunt Nimrata Executive Vice President Feb 14 '24 Option Exercise 0.00 664 0 11,731 Feb 16 05:55 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 14 '24 Option Exercise 0.00 1,731 0 31,449 Feb 16 05:57 PM POLEWACZYK JAMES F Executive Vice President Feb 14 '24 Option Exercise 0.00 927 0 10,990 Feb 16 05:57 PM FENNELL GEORGE SVP, Chief Revenue Officer Feb 08 '24 Option Exercise 62.00 9,810 608,220 14,910 Feb 09 05:03 PM FENNELL GEORGE SVP, Chief Revenue Officer Feb 08 '24 Sale 573.87 8,198 4,704,559 6,712 Feb 09 05:03 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 07 '24 Option Exercise 141.60 23,326 3,302,962 53,044 Feb 09 05:01 PM MAZELSKY JONATHAN JAY President and CEO Feb 07 '24 Option Exercise 67.85 12,000 814,200 91,247 Feb 09 05:00 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 07 '24 Sale 570.01 23,326 13,295,975 29,718 Feb 09 05:01 PM MAZELSKY JONATHAN JAY President and CEO Feb 07 '24 Sale 572.61 12,000 6,871,319 79,247 Feb 09 05:00 PM POLEWACZYK JAMES F Executive Vice President Dec 07 '23 Option Exercise 253.92 11,636 2,954,645 21,686 Dec 08 05:00 PM POLEWACZYK JAMES F Executive Vice President Dec 07 '23 Sale 521.79 11,636 6,071,500 10,050 Dec 08 05:00 PM MAZELSKY JONATHAN JAY President and CEO Dec 04 '23 Option Exercise 79.54 13,424 1,067,745 86,361 Dec 06 05:01 PM MAZELSKY JONATHAN JAY President and CEO Dec 04 '23 Sale 513.05 7,128 3,657,049 79,233 Dec 06 05:01 PM Lane Michael Executive Vice President Nov 07 '23 Option Exercise 133.76 1,728 231,142 5,774 Nov 08 05:09 PM Smith Martin Alexander Executive Vice President Sep 01 '23 Option Exercise 0.00 19 0 226 Sep 06 05:01 PM MAZELSKY JONATHAN JAY President and CEO Aug 31 '23 Option Exercise 79.54 13,424 1,067,745 86,349 Sep 05 05:01 PM MAZELSKY JONATHAN JAY President and CEO Aug 31 '23 Sale 512.01 13,424 6,873,267 72,925 Sep 05 05:01 PM POLEWACZYK JAMES F Executive Vice President Aug 29 '23 Option Exercise 144.21 16,909 2,438,478 32,947 Aug 31 05:17 PM POLEWACZYK JAMES F Executive Vice President Aug 29 '23 Sale 510.56 22,909 11,696,446 10,038 Aug 31 05:17 PM MAZELSKY JONATHAN JAY President and CEO Aug 05 '23 Option Exercise 0.00 384 0 73,095 Aug 08 05:59 PM MCKEON BRIAN P EVP, CFO and Treasurer Aug 05 '23 Option Exercise 0.00 192 0 29,809 Aug 08 05:59 PM Lane Michael Executive Vice President Aug 03 '23 Option Exercise 187.47 16,027 3,004,598 20,061 Aug 07 05:04 PM Lane Michael Executive Vice President Aug 03 '23 Sale 510.00 16,027 8,173,770 4,034 Aug 07 05:04 PM
Index -
P/E -
EPS (ttm) -1.29
Insider Own 19.80%
Shs Outstand 34.34M
Perf Week -3.51%
Market Cap 179.25M
Forward P/E -
EPS next Y -0.96
Insider Trans 0.30%
Shs Float 27.54M
Perf Month 15.49%
Income -27.32M
PEG -
EPS next Q -0.24
Inst Own 48.61%
Short Float 2.73%
Perf Quarter 18.10%
Sales 0.00M
P/S -
EPS this Y 27.71%
Inst Trans 1.44%
Short Ratio 6.09
Perf Half Y -8.74%
Book/sh 1.44
P/B 3.62
EPS next Y 11.77%
ROA -60.15%
Short Interest 0.75M
Perf Year -15.81%
Cash/sh 1.93
P/C 2.70
EPS next 5Y 15.00%
ROE -109.49%
52W Range 3.03 - 6.89
Perf YTD 26.70%
Dividend Est. -
P/FCF -
EPS past 5Y 53.91%
ROI -55.23%
52W High -24.24%
Beta 1.34
Dividend TTM -
Quick Ratio 3.29
Sales past 5Y 0.00%
Gross Margin -
52W Low 72.28%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 3.29
EPS Y/Y TTM 65.82%
Oper. Margin 0.00%
RSI (14) 60.30
Volatility 4.64% 5.13%
Employees 22
Debt/Eq 0.35
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 17.25
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 48.33%
Payout -
Rel Volume 1.35
Prev Close 5.30
Sales Surprise -
EPS Surprise -7.57%
Sales Q/Q -
Earnings May 09 AMC
Avg Volume 123.25K
Price 5.22
SMA20 4.56%
SMA50 11.00%
SMA200 15.43%
Trades
Volume 166,486
Change -1.51%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-23 Reiterated
Maxim Group
Buy
$8 → $20
Jun-23-21 Initiated
Oppenheimer
Outperform
$23
May-29-24 08:00AM
May-17-24 08:00AM
May-13-24 08:55AM
May-10-24 03:47PM
12:41PM
04:01PM
Loading…
May-09-24 04:01PM
May-06-24 11:16AM
Apr-29-24 09:00AM
Apr-25-24 08:00AM
Apr-11-24 08:00AM
Apr-01-24 03:30PM
Mar-29-24 06:24AM
(Thomson Reuters StreetEvents)
Mar-28-24 08:53PM
05:32PM
04:01PM
08:00AM
Loading…
Mar-20-24 08:00AM
Mar-14-24 08:00AM
Mar-08-24 08:35AM
Mar-06-24 08:00AM
Mar-05-24 08:35AM
Feb-29-24 08:01AM
08:00AM
Dec-15-23 08:35AM
Dec-13-23 08:00AM
Dec-12-23 01:02PM
09:10AM
Dec-11-23 04:30PM
Nov-11-23 10:36AM
Nov-10-23 10:01AM
(Thomson Reuters StreetEvents)
Nov-09-23 04:00PM
08:00AM
Loading…
Oct-26-23 08:00AM
Oct-03-23 08:00AM
Sep-11-23 08:00AM
Sep-07-23 08:00AM
Aug-16-23 10:30AM
Aug-15-23 10:25PM
(Thomson Reuters StreetEvents)
Aug-14-23 04:00PM
Aug-01-23 08:00AM
Jul-18-23 08:00AM
Jul-11-23 11:23AM
May-25-23 09:00AM
07:16AM
(Zacks Small Cap Research)
May-24-23 06:10AM
May-23-23 02:46PM
06:00AM
May-17-23 08:00AM
May-10-23 09:08AM
(Zacks Small Cap Research) +12.71%
05:57AM
(Thomson Reuters StreetEvents)
May-09-23 04:05PM
Apr-26-23 08:00AM
Apr-24-23 05:27AM
(Zacks Small Cap Research)
Apr-20-23 02:22PM
08:00AM
Apr-14-23 08:00AM
Mar-30-23 08:00AM
Mar-29-23 08:00AM
Mar-20-23 10:46PM
05:27AM
(Zacks Small Cap Research)
Mar-17-23 08:00AM
05:48AM
(Thomson Reuters StreetEvents)
Mar-16-23 04:05PM
Mar-08-23 08:00AM
Mar-03-23 08:00AM
Mar-02-23 08:00AM
Feb-15-23 05:42AM
(Simply Wall St.) -15.52%
Feb-07-23 08:00AM
Feb-02-23 08:00AM
Jan-27-23 04:30PM
Jan-09-23 08:00AM
Dec-29-22 06:02AM
Dec-21-22 08:00AM
Nov-21-22 06:01AM
(Zacks Small Cap Research)
Nov-15-22 08:00AM
Nov-14-22 04:05PM
Nov-08-22 08:00AM
Oct-31-22 08:00AM
Sep-27-22 08:00AM
Sep-07-22 08:00AM
Aug-15-22 06:16AM
(Zacks Small Cap Research) +12.80%
Aug-11-22 04:05PM
Jul-28-22 08:00AM
Jul-01-22 04:05PM
Jun-29-22 08:00AM
Jun-21-22 08:00AM
Jun-01-22 08:00AM
May-26-22 08:00AM
May-16-22 01:20PM
May-13-22 08:00AM
06:30AM
(Zacks Small Cap Research)
May-12-22 04:00PM
May-05-22 02:59PM
Apr-28-22 05:22AM
(Zacks Small Cap Research) -6.46%
Apr-27-22 09:40AM
08:00AM
Apr-21-22 08:00AM
Mar-15-22 08:00AM
Mar-14-22 08:00AM
Mar-11-22 08:06AM
(Zacks Small Cap Research)
08:00AM
Mar-10-22 08:00AM
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wan Jerry Principal Accounting Officer Apr 19 '24 Option Exercise 0.00 5,625 0 12,057 Apr 23 04:39 PM JACOBS CINDY President & CMO Apr 19 '24 Option Exercise 0.00 16,250 0 34,511 Apr 23 04:35 PM Stewart Richard Alistair Executive Chairman Apr 19 '24 Option Exercise 0.00 22,500 0 61,001 Apr 23 04:31 PM Bencich John CEO Apr 19 '24 Option Exercise 0.00 25,000 0 101,724 Apr 23 04:26 PM Stewart Richard Alistair Executive Chairman Mar 04 '24 Buy 4.58 10,000 45,850 38,501 Mar 06 04:49 PM Bencich John CEO Mar 04 '24 Buy 4.58 10,000 45,850 76,724 Mar 06 04:43 PM
Index RUT
P/E -
EPS (ttm) -5.37
Insider Own 1.88%
Shs Outstand 96.48M
Perf Week -14.07%
Market Cap 2.06B
Forward P/E -
EPS next Y -5.45
Insider Trans -2.86%
Shs Float 94.66M
Perf Month -4.98%
Income -485.50M
PEG -
EPS next Q -1.21
Inst Own 91.41%
Short Float 16.02%
Perf Quarter -34.54%
Sales 52.60M
P/S 39.22
EPS this Y 6.14%
Inst Trans -0.30%
Short Ratio 11.32
Perf Half Y -30.88%
Book/sh 10.76
P/B 1.99
EPS next Y -7.20%
ROA -36.27%
Short Interest 15.17M
Perf Year -42.62%
Cash/sh 8.20
P/C 2.61
EPS next 5Y 30.00%
ROE -43.60%
52W Range 19.37 - 47.48
Perf YTD -29.88%
Dividend Est. -
P/FCF -
EPS past 5Y -22.30%
ROI -43.03%
52W High -54.97%
Beta 1.85
Dividend TTM -
Quick Ratio 9.03
Sales past 5Y 12.09%
Gross Margin 82.06%
52W Low 10.38%
ATR (14) 1.23
Dividend Ex-Date -
Current Ratio 9.03
EPS Y/Y TTM 0.38%
Oper. Margin -983.45%
RSI (14) 34.64
Volatility 5.30% 4.72%
Employees 526
Debt/Eq 0.11
Sales Y/Y TTM -1.63%
Profit Margin -922.94%
Recom 1.52
Target Price 69.25
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 4.25%
Payout -
Rel Volume 1.39
Prev Close 22.10
Sales Surprise 157.37%
EPS Surprise 18.02%
Sales Q/Q 129.53%
Earnings May 09 BMO
Avg Volume 1.34M
Price 21.38
SMA20 -12.79%
SMA50 -11.89%
SMA200 -25.28%
Trades
Volume 1,867,705
Change -3.26%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Feb-07-22 Upgrade
Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated
Cowen
Outperform
Jan-07-22 Initiated
Piper Sandler
Overweight
$171
Oct-05-21 Initiated
Guggenheim
Buy
$170
Sep-24-21 Initiated
Stifel
Buy
$173
Show Previous Ratings
May-25-24 08:30AM
May-22-24 11:15AM
May-14-24 12:46PM
09:30AM
May-13-24 02:18PM
03:35PM
Loading…
May-10-24 03:35PM
01:16PM
11:45AM
11:26AM
May-09-24 11:53PM
(Thomson Reuters StreetEvents) +8.09%
11:42AM
08:49AM
08:40AM
07:30AM
May-03-24 06:15PM
02:18PM
Loading…
02:18PM
May-02-24 07:30AM
06:04AM
Apr-29-24 07:30AM
Apr-25-24 11:21AM
10:01AM
Apr-14-24 05:55AM
Apr-12-24 04:50AM
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
10:35AM
Loading…
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
(Investor's Business Daily)
07:00AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM Bhanji Muna Director Jul 31 '23 Sale 42.33 265 11,217 12,261 Aug 02 05:19 PM Bhanji Muna Director Jul 06 '23 Sale 39.30 1,867 73,373 12,526 Jul 10 05:21 PM Clark Eliana EVP, Chief Technical Officer Jul 03 '23 Sale 40.51 360 14,584 45,146 Jul 06 03:34 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Option Exercise 12.27 5,000 61,350 50,146 Jun 22 05:52 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Sale 45.00 5,000 225,000 45,146 Jun 22 05:52 PM
Index -
P/E -
EPS (ttm) -1.05
Insider Own 74.60%
Shs Outstand 40.79M
Perf Week 2.92%
Market Cap 71.84M
Forward P/E -
EPS next Y -0.59
Insider Trans 0.04%
Shs Float 10.37M
Perf Month -7.85%
Income -36.06M
PEG -
EPS next Q -0.17
Inst Own 14.69%
Short Float 0.34%
Perf Quarter -38.46%
Sales 36.85M
P/S 1.95
EPS this Y 41.16%
Inst Trans -1.24%
Short Ratio 3.17
Perf Half Y -12.87%
Book/sh 2.04
P/B 0.86
EPS next Y 13.19%
ROA -27.54%
Short Interest 0.04M
Perf Year -54.17%
Cash/sh 0.53
P/C 3.33
EPS next 5Y -
ROE -41.10%
52W Range 1.66 - 4.27
Perf YTD -52.82%
Dividend Est. -
P/FCF -
EPS past 5Y -113.92%
ROI -31.96%
52W High -58.78%
Beta 0.41
Dividend TTM -
Quick Ratio 3.92
Sales past 5Y 17.33%
Gross Margin 24.24%
52W Low 6.02%
ATR (14) 0.16
Dividend Ex-Date -
Current Ratio 5.52
EPS Y/Y TTM 41.76%
Oper. Margin -78.53%
RSI (14) 42.66
Volatility 6.81% 7.55%
Employees 211
Debt/Eq 0.38
Sales Y/Y TTM -6.45%
Profit Margin -97.85%
Recom 1.80
Target Price 5.50
Option/Short No / Yes
LT Debt/Eq 0.35
EPS Q/Q 36.59%
Payout -
Rel Volume 0.28
Prev Close 1.84
Sales Surprise 9.89%
EPS Surprise 17.53%
Sales Q/Q 1.85%
Earnings May 13 AMC
Avg Volume 11.07K
Price 1.76
SMA20 -3.96%
SMA50 -16.37%
SMA200 -30.12%
Trades
Volume 3,111
Change -4.35%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-24 Downgrade
BTIG Research
Buy → Neutral
May-23-24 07:57AM
May-13-24 08:55PM
04:17PM
(Associated Press Finance)
04:01PM
May-07-24 10:00AM
04:01PM
Loading…
Apr-29-24 04:01PM
Apr-24-24 09:35AM
Mar-13-24 08:12AM
Mar-11-24 05:35PM
04:24PM
(Associated Press Finance)
04:01PM
Feb-21-24 04:01PM
Nov-16-23 04:15AM
Nov-12-23 11:53AM
Nov-09-23 04:39PM
(Associated Press Finance)
04:01PM
Loading…
04:01PM
Oct-26-23 08:00AM
Sep-27-23 08:00AM
Sep-26-23 09:56AM
Sep-19-23 04:01PM
Sep-18-23 08:00AM
Aug-16-23 08:00AM
Aug-15-23 10:20AM
Aug-14-23 09:12AM
Aug-10-23 04:31PM
04:01PM
Aug-09-23 08:00AM
Jul-26-23 08:00AM
Jul-20-23 08:00AM
Jul-16-23 09:30AM
08:00AM
Loading…
Jul-11-23 08:00AM
Jun-05-23 12:40PM
May-29-23 02:34AM
May-25-23 08:00AM
May-10-23 04:13PM
04:01PM
08:00AM
May-04-23 12:00PM
08:00AM
May-02-23 08:00AM
Apr-26-23 08:00AM
Apr-24-23 09:35AM
Apr-17-23 06:12AM
Apr-07-23 09:35AM
Mar-18-23 02:55AM
Mar-15-23 04:01PM
08:00AM
Feb-23-23 08:00AM
Feb-10-23 08:00AM
Feb-06-23 07:06AM
Dec-27-22 10:02AM
Dec-18-22 04:42PM
Nov-16-22 05:44AM
Nov-12-22 08:07AM
Nov-09-22 04:01PM
08:00AM
Nov-03-22 04:01PM
Oct-26-22 04:01PM
Oct-18-22 09:03AM
Oct-13-22 08:00AM
Oct-05-22 08:00AM
Aug-31-22 04:01PM
Aug-17-22 06:08AM
(Simply Wall St.) -11.23%
Aug-13-22 08:35AM
Aug-10-22 04:01PM
Aug-01-22 04:01PM
Jul-05-22 09:39AM
(Simply Wall St.) -10.91%
Jun-05-22 09:12AM
May-25-22 04:01PM
May-11-22 04:01PM
May-04-22 05:18PM
Mar-15-22 04:01PM
Mar-02-22 08:05AM
Feb-28-22 08:15AM
Feb-14-22 08:00AM
Jan-28-22 01:38PM
Dec-27-21 11:38PM
11:56AM
Dec-15-21 06:02PM
Nov-16-21 05:03PM
Nov-10-21 04:01PM
07:00AM
Nov-03-21 04:05PM
Oct-08-21 12:42PM
(American City Business Journals)
Aug-11-21 04:01PM
Aug-04-21 04:05PM
Jun-29-21 07:00PM
Jun-24-21 10:00PM
Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gelhaus Ken Chief Commercial Officer Nov 30 '23 Buy 1.73 3,587 6,220 22,924 Dec 01 05:44 PM Telegraph Hill Partners IV, L. 10% Owner Sep 19 '23 Buy 1.85 6,917,837 12,797,998 21,859,660 Sep 21 08:58 PM Telegraph Hill Partners IV, L. 10% Owner Sep 19 '23 Buy 1.85 1,190,270 2,202,000 3,761,132 Sep 21 08:58 PM MACKOWSKI J MATTHEW Director Sep 19 '23 Buy 1.85 810,810 1,499,998 810,810 Sep 21 05:04 PM Gunstream Stephen President and CEO Sep 19 '23 Buy 1.85 54,054 100,000 162,852 Sep 21 05:03 PM Lowell Matthew Chief Financial Officer Sep 19 '23 Buy 1.85 54,054 100,000 88,054 Sep 21 05:03 PM Terrill Damon General Counsel and CCO Sep 19 '23 Buy 1.85 27,027 50,000 41,027 Sep 21 05:04 PM Hood Lisa Chief People Officer Jun 13 '23 Sale 3.80 11,400 43,268 33,834 Jun 14 04:55 PM
Index -
P/E -
EPS (ttm) -26.38
Insider Own 22.27%
Shs Outstand 66.70M
Perf Week 5.59%
Market Cap 2.96B
Forward P/E 12.93
EPS next Y 3.42
Insider Trans 0.01%
Shs Float 52.06M
Perf Month 11.37%
Income -1764.90M
PEG -
EPS next Q -0.22
Inst Own 78.27%
Short Float 6.33%
Perf Quarter -2.94%
Sales 2.86B
P/S 1.04
EPS this Y -54.03%
Inst Trans 0.57%
Short Ratio 3.51
Perf Half Y -36.98%
Book/sh 49.52
P/B 0.89
EPS next Y 79.97%
ROA -22.79%
Short Interest 3.30M
Perf Year -48.10%
Cash/sh 1.17
P/C 37.70
EPS next 5Y 7.20%
ROE -42.51%
52W Range 37.78 - 89.11
Perf YTD -40.04%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -30.80%
52W High -50.41%
Beta 0.12
Dividend TTM -
Quick Ratio 0.81
Sales past 5Y 59.83%
Gross Margin 40.71%
52W Low 16.97%
ATR (14) 1.74
Dividend Ex-Date -
Current Ratio 1.55
EPS Y/Y TTM -1528.78%
Oper. Margin 4.29%
RSI (14) 55.49
Volatility 3.39% 4.45%
Employees 7100
Debt/Eq 0.79
Sales Y/Y TTM -8.06%
Profit Margin -61.79%
Recom 2.38
Target Price 53.34
Option/Short Yes / Yes
LT Debt/Eq 0.73
EPS Q/Q -3606.23%
Payout -
Rel Volume 0.69
Prev Close 44.20
Sales Surprise 2.56%
EPS Surprise 12.79%
Sales Q/Q -16.03%
Earnings May 08 AMC
Avg Volume 939.90K
Price 44.19
SMA20 2.58%
SMA50 3.01%
SMA200 -27.19%
Trades
Volume 648,432
Change -0.02%
Index -
P/E -
EPS (ttm) -2.67
Insider Own 8.08%
Shs Outstand 144.34M
Perf Week -1.13%
Market Cap 5.48B
Forward P/E -
EPS next Y -3.32
Insider Trans -3.81%
Shs Float 134.17M
Perf Month -12.65%
Income -384.50M
PEG -
EPS next Q -0.98
Inst Own 96.91%
Short Float 6.43%
Perf Quarter -17.36%
Sales 777.12M
P/S 7.06
EPS this Y -52.67%
Inst Trans -4.52%
Short Ratio 8.25
Perf Half Y -23.96%
Book/sh 2.03
P/B 18.48
EPS next Y 15.09%
ROA -13.61%
Short Interest 8.63M
Perf Year -8.14%
Cash/sh 15.11
P/C 2.49
EPS next 5Y 35.30%
ROE -98.20%
52W Range 36.25 - 54.44
Perf YTD -25.74%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -17.31%
52W High -30.99%
Beta 0.35
Dividend TTM -
Quick Ratio 7.28
Sales past 5Y 13.97%
Gross Margin 95.83%
52W Low 3.64%
ATR (14) 1.30
Dividend Ex-Date -
Current Ratio 7.37
EPS Y/Y TTM -15.53%
Oper. Margin -50.05%
RSI (14) 41.65
Volatility 3.19% 3.36%
Employees 927
Debt/Eq 6.64
Sales Y/Y TTM 34.90%
Profit Margin -49.48%
Recom 1.84
Target Price 57.56
Option/Short Yes / Yes
LT Debt/Eq 6.49
EPS Q/Q -12.65%
Payout -
Rel Volume 1.29
Prev Close 36.55
Sales Surprise -9.45%
EPS Surprise 5.12%
Sales Q/Q -8.45%
Earnings May 07 BMO
Avg Volume 1.05M
Price 37.57
SMA20 -3.44%
SMA50 -8.46%
SMA200 -16.96%
Trades
Volume 1,346,242
Change 2.79%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-10-24 Upgrade
Wolfe Research
Peer Perform → Outperform
$58
Jan-02-24 Upgrade
BofA Securities
Neutral → Buy
$52 → $62
Oct-23-23 Upgrade
BofA Securities
Underperform → Neutral
$33 → $52
Sep-29-23 Initiated
Raymond James
Strong Buy
$63
Jul-31-23 Upgrade
Citigroup
Neutral → Buy
$36 → $60
Jun-07-23 Resumed
Piper Sandler
Overweight
$58
May-04-23 Upgrade
Citigroup
Sell → Neutral
$30 → $36
Mar-21-23 Initiated
Bernstein
Underperform
$31
Dec-21-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$56 → $40
Sep-09-22 Resumed
Morgan Stanley
Overweight
$57
Jul-18-22 Resumed
Oppenheimer
Outperform
$59
Mar-31-22 Resumed
Piper Sandler
Overweight
$54
Mar-01-22 Initiated
Guggenheim
Buy
$64
Mar-01-22 Initiated
Citigroup
Sell
$26
Feb-01-22 Downgrade
BofA Securities
Buy → Underperform
$40 → $30
Dec-14-21 Upgrade
William Blair
Mkt Perform → Outperform
May-07-21 Upgrade
UBS
Sell → Neutral
$33 → $37.50
Mar-01-21 Upgrade
Barclays
Underweight → Equal Weight
$50 → $52
Dec-16-20 Initiated
UBS
Sell
$34
Dec-15-20 Upgrade
Cowen
Market Perform → Outperform
Show Previous Ratings
May-31-24 12:25PM
07:00AM
May-28-24 07:00AM
May-23-24 07:00AM
May-17-24 10:10AM
12:46PM
Loading…
May-16-24 12:46PM
10:54AM
08:50AM
08:05AM
07:51AM
07:37AM
07:30AM
07:30AM
07:00AM
May-15-24 07:05AM
07:00AM
Loading…
May-13-24 07:00AM
May-09-24 06:30AM
May-08-24 03:15PM
10:59AM
10:39AM
05:20AM
(Thomson Reuters StreetEvents)
03:40AM
May-07-24 05:02PM
04:43PM
09:30AM
08:10AM
08:07AM
07:07AM
(Associated Press Finance)
07:00AM
May-06-24 09:15AM
10:00AM
Loading…
Apr-30-24 10:00AM
Apr-25-24 07:00AM
Apr-23-24 07:05AM
Apr-07-24 09:48AM
Apr-01-24 07:05AM
Mar-28-24 07:05AM
Mar-25-24 09:09AM
08:18AM
Mar-22-24 11:30AM
Mar-21-24 03:00PM
(The Wall Street Journal)
Mar-17-24 08:50AM
Mar-14-24 10:40AM
Mar-13-24 07:17AM
07:07AM
07:00AM
Mar-06-24 07:30AM
Feb-29-24 09:05AM
Feb-28-24 07:05AM
Feb-22-24 12:12PM
10:59AM
10:29AM
02:20AM
(Thomson Reuters StreetEvents)
Feb-21-24 11:31AM
09:30AM
08:05AM
07:06AM
(Associated Press Finance)
07:00AM
Feb-15-24 09:15AM
07:00AM
Feb-14-24 10:00AM
Feb-09-24 10:44AM
Feb-08-24 07:00AM
Feb-07-24 07:05AM
Jan-23-24 01:23PM
Jan-22-24 07:26AM
07:09AM
07:00AM
04:47AM
Jan-18-24 07:58PM
Jan-08-24 08:00AM
07:03AM
Jan-03-24 08:00AM
Dec-30-23 07:01AM
Dec-27-23 10:34PM
Dec-24-23 11:01AM
Dec-21-23 06:55PM
05:45PM
05:35PM
Dec-20-23 01:50PM
07:05AM
Dec-19-23 10:45AM
Dec-18-23 04:01PM
Dec-14-23 04:05PM
Dec-07-23 08:47PM
Nov-16-23 08:00AM
Nov-13-23 09:46AM
Nov-11-23 11:30AM
Nov-09-23 12:42PM
Nov-04-23 01:01PM
Nov-03-23 06:36PM
(Morningstar Research) +7.91%
09:44AM
07:05AM
05:09AM
(Thomson Reuters StreetEvents)
Nov-02-23 12:36PM
09:30AM
07:19AM
(Associated Press Finance)
07:00AM
Oct-31-23 10:01AM
Oct-30-23 03:46PM
Oct-26-23 10:02AM
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WENDER JOSEPH H Director May 09 '24 Option Exercise 35.53 16,000 568,480 128,079 May 13 05:25 PM KLEIN JOSEPH III Director May 03 '24 Sale 42.71 6,000 256,277 0 May 07 04:55 PM Baroldi Joseph EVP, Chief Business Officer Apr 16 '24 Sale 41.60 4,006 166,641 19,631 Apr 17 05:19 PM Birchler Brian EVP, Corp and Development Ops Apr 16 '24 Sale 41.66 905 37,698 46,156 Apr 17 05:16 PM Baroldi Joseph EVP, Chief Business Officer Apr 15 '24 Option Exercise 0.00 10,838 0 23,637 Apr 17 05:19 PM Birchler Brian EVP, Corp and Development Ops Apr 15 '24 Option Exercise 0.00 1,875 0 47,061 Apr 17 05:16 PM Monia Brett P Chief Executive Officer Feb 16 '24 Sale 44.49 387 17,219 173,751 Feb 16 07:47 PM Monia Brett P Chief Executive Officer Feb 02 '24 Sale 49.37 23,501 1,160,303 174,138 Feb 02 07:55 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Feb 02 '24 Sale 49.60 2,125 105,404 35,825 Feb 02 07:54 PM HOUGEN ELIZABETH L EVP, Finance & CFO Feb 02 '24 Sale 49.54 2,125 105,272 92,905 Feb 02 07:55 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Feb 02 '24 Sale 49.59 2,071 102,701 49,812 Feb 02 07:55 PM Geary Richard S EVP, Chief Development Officer Feb 02 '24 Sale 50.04 1,961 98,135 87,334 Feb 02 07:54 PM O'NEIL PATRICK R. EVP CLO & General Counsel Feb 02 '24 Sale 49.67 1,961 97,410 48,661 Feb 02 07:55 PM Swayze Eric EVP Research Feb 02 '24 Sale 49.56 1,907 94,513 34,324 Feb 02 07:55 PM BENNETT C FRANK EVP, Chief Scientific Officer Feb 02 '24 Sale 49.52 1,853 91,752 79,079 Feb 02 07:54 PM Swayze Eric EVP Research Jan 31 '24 Sale 52.00 10,773 560,196 32,516 Feb 02 07:55 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 25 '24 Sale 51.75 6,450 333,788 46,802 Jan 29 05:34 PM Monia Brett P Chief Executive Officer Jan 25 '24 Sale 51.75 2,285 118,249 151,851 Jan 29 05:34 PM Monia Brett P Chief Executive Officer Jan 17 '24 Sale 50.42 32,059 1,616,319 154,136 Jan 18 05:48 PM HOUGEN ELIZABETH L EVP, Finance & CFO Jan 17 '24 Sale 50.42 8,683 437,771 90,890 Jan 18 05:48 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 17 '24 Sale 50.42 7,744 390,429 53,252 Jan 18 05:59 PM Geary Richard S EVP, Chief Development Officer Jan 17 '24 Sale 50.42 7,338 369,960 85,475 Jan 18 05:47 PM BENNETT C FRANK EVP, Chief Scientific Officer Jan 17 '24 Sale 50.42 6,745 340,063 77,323 Jan 18 05:44 PM Swayze Eric EVP Research Jan 17 '24 Sale 50.42 6,296 317,425 43,289 Jan 18 05:49 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Jan 17 '24 Sale 50.42 5,564 280,520 33,810 Jan 18 06:07 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 17 '24 Sale 50.42 5,482 276,386 47,850 Jan 18 05:48 PM Birchler Brian EVP, Corp and Development Ops Jan 17 '24 Sale 50.42 4,497 226,725 44,582 Jan 18 05:55 PM Baroldi Joseph EVP, Chief Business Officer Jan 17 '24 Sale 50.42 1,460 73,609 12,799 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 17 '24 Sale 50.42 564 28,435 1,640 Jan 18 05:44 PM Swayze Eric EVP Research Jan 17 '24 Sale 50.42 9 454 85 Jan 18 05:49 PM Baroldi Joseph EVP, Chief Business Officer Jan 16 '24 Option Exercise 0.00 1,353 0 2,204 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 16 '24 Option Exercise 0.00 3,688 0 14,259 Jan 18 05:44 PM BENNETT C FRANK EVP, Chief Scientific Officer Jan 16 '24 Option Exercise 0.00 18,314 0 84,068 Jan 18 05:44 PM HOUGEN ELIZABETH L EVP, Finance & CFO Jan 16 '24 Option Exercise 0.00 22,487 0 99,573 Jan 18 05:48 PM Monia Brett P Chief Executive Officer Jan 16 '24 Option Exercise 0.00 68,084 0 186,195 Jan 18 05:48 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Jan 16 '24 Option Exercise 0.00 15,062 0 39,374 Jan 18 06:07 PM Birchler Brian EVP, Corp and Development Ops Jan 16 '24 Option Exercise 0.00 12,080 0 49,079 Jan 18 05:55 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 16 '24 Option Exercise 0.00 20,641 0 60,996 Jan 18 05:59 PM Geary Richard S EVP, Chief Development Officer Jan 16 '24 Option Exercise 0.00 19,852 0 92,813 Jan 18 05:47 PM Swayze Eric EVP Research Jan 16 '24 Option Exercise 0.00 21 0 94 Jan 18 05:49 PM Swayze Eric EVP Research Jan 16 '24 Option Exercise 0.00 17,069 0 49,585 Jan 18 05:49 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 16 '24 Option Exercise 0.00 15,162 0 53,332 Jan 18 05:48 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 12 '24 Option Exercise 32.60 8,000 260,800 46,170 Jan 17 08:51 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 12 '24 Sale 53.50 8,000 427,999 38,170 Jan 17 08:51 PM HOUGEN ELIZABETH L EVP, Finance & CFO Dec 28 '23 Option Exercise 47.34 45,225 2,140,952 120,884 Jan 02 05:54 PM PARSHALL B LYNNE Director Dec 28 '23 Option Exercise 47.34 42,525 2,013,134 125,113 Dec 28 07:18 PM Swayze Eric EVP Research Dec 28 '23 Option Exercise 47.34 27,100 1,282,914 59,616 Jan 02 05:54 PM Birchler Brian EVP, Corp and Development Ops Dec 28 '23 Option Exercise 47.34 11,500 544,410 48,028 Jan 02 05:54 PM PARSHALL B LYNNE Director Dec 28 '23 Sale 50.19 42,525 2,134,223 82,588 Dec 28 07:18 PM Swayze Eric EVP Research Dec 28 '23 Sale 50.19 27,100 1,360,081 32,516 Jan 02 05:54 PM PARSHALL B LYNNE Director Dec 27 '23 Option Exercise 47.34 50,000 2,367,000 132,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 27 '23 Sale 50.23 50,000 2,511,515 82,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 26 '23 Option Exercise 47.34 25,113 1,188,849 107,701 Dec 28 07:18 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Dec 26 '23 Option Exercise 47.34 25,000 1,183,500 61,052 Dec 28 07:18 PM O'NEIL PATRICK R. EVP CLO & General Counsel Dec 26 '23 Option Exercise 47.34 20,825 985,856 61,180 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 26 '23 Sale 51.46 25,113 1,292,390 82,588 Dec 28 07:18 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Dec 26 '23 Sale 51.46 25,000 1,286,575 36,052 Dec 28 07:18 PM O'NEIL PATRICK R. EVP CLO & General Counsel Dec 26 '23 Sale 51.46 20,825 1,071,717 40,355 Dec 28 07:18 PM Monia Brett P Chief Executive Officer Dec 21 '23 Option Exercise 47.34 17,500 828,450 135,611 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 21 '23 Option Exercise 47.34 16,113 762,789 81,867 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 21 '23 Option Exercise 47.34 4,112 194,662 77,073 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 21 '23 Sale 49.29 17,500 862,577 118,111 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 21 '23 Sale 49.29 16,113 794,211 65,754 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 21 '23 Sale 49.29 4,112 202,681 72,961 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 124,611 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 72,254 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 79,461 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 20 '23 Sale 49.64 6,500 322,643 118,111 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 20 '23 Sale 49.64 6,500 322,643 72,961 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 20 '23 Sale 49.64 6,500 322,643 65,754 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 14 '23 Option Exercise 47.34 24,000 1,136,160 132,971 Dec 18 04:56 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 14 '23 Option Exercise 47.34 22,612 1,070,452 79,756 Dec 18 04:55 PM Geary Richard S EVP, Chief Development Officer Dec 14 '23 Option Exercise 47.34 10,613 502,419 79,532 Dec 18 04:55 PM Monia Brett P Chief Executive Officer Dec 14 '23 Sale 49.58 24,000 1,190,019 118,111 Dec 18 04:56 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 14 '23 Sale 49.58 22,612 1,121,195 65,754 Dec 18 04:55 PM Geary Richard S EVP, Chief Development Officer Dec 14 '23 Sale 49.58 10,613 526,236 72,961 Dec 18 04:55 PM KLEIN JOSEPH III Director Nov 15 '23 Sale 50.00 2,000 100,000 16,346 Nov 17 04:58 PM Swayze Eric EVP Research Oct 17 '23 Sale 47.95 52 2,493 73 Oct 18 06:40 PM Swayze Eric EVP Research Oct 16 '23 Option Exercise 0.00 125 0 125 Oct 18 06:40 PM Monia Brett P Chief Executive Officer Oct 12 '23 Sale 46.00 3,770 173,420 118,111 Oct 16 04:35 PM BENNETT C FRANK EVP, Chief Scientific Officer Sep 28 '23 Sale 46.50 4,460 207,390 65,754 Sep 29 05:20 PM PARSHALL B LYNNE Director Sep 26 '23 Sale 45.13 10,000 451,268 82,588 Sep 28 06:03 PM KLEIN JOSEPH III Director Sep 26 '23 Sale 45.13 2,000 90,254 18,346 Sep 28 06:03 PM Diaz Allene M. Director Aug 01 '23 Sale 41.05 657 26,970 12,676 Aug 03 05:20 PM KLEIN JOSEPH III Director Jul 18 '23 Sale 42.00 3,555 149,310 20,346 Jul 19 06:05 PM BERTHELSEN SPENCER R Director Jul 17 '23 Option Exercise 0.00 7,110 0 147,257 Jul 19 06:05 PM WENDER JOSEPH H Director Jul 17 '23 Option Exercise 0.00 7,110 0 112,079 Jul 19 06:08 PM Diaz Allene M. Director Jul 17 '23 Option Exercise 0.00 5,333 0 13,333 Jul 19 06:05 PM Hayden Michael R Director Jul 17 '23 Option Exercise 0.00 7,110 0 30,219 Jul 19 06:05 PM HERMAN JOAN E Director Jul 17 '23 Option Exercise 0.00 7,110 0 37,330 Jul 19 06:05 PM KLEIN JOSEPH III Director Jul 17 '23 Option Exercise 0.00 7,110 0 23,901 Jul 19 06:05 PM LOSCALZO JOSEPH Director Jul 17 '23 Option Exercise 0.00 7,110 0 41,082 Jul 19 06:06 PM PARSHALL B LYNNE Director Jul 17 '23 Option Exercise 0.00 7,110 0 92,588 Jul 19 06:06 PM Monia Brett P Chief Executive Officer Jul 07 '23 Sale 42.25 18,650 787,953 121,724 Jul 11 05:07 PM BERTHELSEN SPENCER R Director Jun 20 '23 Option Exercise 28.47 11,250 320,288 140,147 Jun 22 05:17 PM HERMAN JOAN E Director Jun 12 '23 Option Exercise 0.00 3,555 0 30,220 Jun 14 04:50 PM
Index -
P/E -
EPS (ttm) -1.44
Insider Own 38.11%
Shs Outstand 10.65M
Perf Week 6.01%
Market Cap 30.75M
Forward P/E -
EPS next Y -0.91
Insider Trans 0.08%
Shs Float 7.70M
Perf Month -23.29%
Income -14.74M
PEG -
EPS next Q -0.33
Inst Own 15.20%
Short Float 2.18%
Perf Quarter -38.17%
Sales 8.99M
P/S 3.42
EPS this Y 24.72%
Inst Trans 60.38%
Short Ratio 5.89
Perf Half Y -23.05%
Book/sh -0.11
P/B -
EPS next Y 33.39%
ROA -158.00%
Short Interest 0.17M
Perf Year -23.05%
Cash/sh 0.27
P/C 9.02
EPS next 5Y -
ROE -701.30%
52W Range 2.00 - 6.75
Perf YTD -39.46%
Dividend Est. -
P/FCF -
EPS past 5Y 5.77%
ROI -3129.72%
52W High -63.41%
Beta 1.50
Dividend TTM -
Quick Ratio 1.11
Sales past 5Y 25.92%
Gross Margin 58.84%
52W Low 23.28%
ATR (14) 0.28
Dividend Ex-Date Dec 16, 2016
Current Ratio 1.16
EPS Y/Y TTM 91.26%
Oper. Margin -192.21%
RSI (14) 40.08
Volatility 11.98% 11.84%
Employees 64
Debt/Eq -
Sales Y/Y TTM 4.46%
Profit Margin -163.95%
Recom 2.33
Target Price 5.25
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 46.45%
Payout -
Rel Volume 2.31
Prev Close 2.15
Sales Surprise -16.00%
EPS Surprise -17.19%
Sales Q/Q -7.04%
Earnings May 15 BMO
Avg Volume 28.51K
Price 2.47
SMA20 -9.15%
SMA50 -18.96%
SMA200 -37.92%
Trades
Volume 65,936
Change 14.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-12-22 Resumed
Cantor Fitzgerald
Overweight
$4
Mar-29-21 Initiated
Truist
Buy
$12
Jan-29-21 Initiated
Cantor Fitzgerald
Overweight
$10
Oct-30-20 Initiated
William Blair
Outperform
May-16-24 08:00AM
May-15-24 11:53AM
08:40AM
07:30AM
May-08-24 08:47AM
08:00AM
Loading…
08:00AM
May-07-24 08:00AM
May-02-24 08:00AM
Apr-09-24 08:00AM
Apr-01-24 11:24AM
Mar-28-24 11:53AM
07:30AM
Mar-25-24 08:00AM
Mar-21-24 08:00AM
Mar-18-24 08:00AM
08:00AM
Loading…
Mar-11-24 08:00AM
Feb-22-24 08:30AM
Feb-12-24 08:00AM
Feb-06-24 08:00AM
Jan-25-24 08:00AM
07:30AM
Dec-19-23 08:00AM
Dec-14-23 08:00AM
Dec-08-23 09:46AM
Dec-07-23 09:20AM
Dec-06-23 08:00AM
Nov-28-23 08:00AM
Nov-27-23 09:47AM
Nov-13-23 04:05PM
Nov-09-23 08:00AM
08:00AM
Loading…
Oct-31-23 08:00AM
Oct-25-23 08:00AM
Oct-23-23 08:00AM
Oct-20-23 10:43AM
Sep-29-23 08:00AM
Sep-13-23 08:00AM
Sep-11-23 08:00AM
Aug-31-23 08:00AM
Aug-29-23 08:00AM
Aug-28-23 08:00AM
Aug-14-23 04:01PM
Aug-09-23 04:05PM
Jul-31-23 08:00AM
Jul-20-23 08:30AM
Jun-28-23 08:00AM
Jun-12-23 06:23PM
Jun-08-23 01:23PM
01:23PM
Jun-05-23 08:00AM
Jun-02-23 09:35AM
08:00AM
May-31-23 08:00AM
May-30-23 08:00AM
May-26-23 09:15AM
May-19-23 09:38AM
08:00AM
May-16-23 04:05PM
May-15-23 04:05PM
09:00AM
May-11-23 04:01PM
12:33PM
09:45AM
08:00AM
May-09-23 04:07PM
Apr-27-23 04:05PM
Mar-27-23 07:12AM
Mar-22-23 04:05PM
Mar-03-23 08:38AM
08:00AM
Jan-09-23 04:05PM
Jan-06-23 08:00AM
Dec-27-22 08:00AM
Nov-29-22 04:01PM
Nov-10-22 07:00AM
Nov-01-22 08:00AM
Oct-06-22 04:05PM
Oct-05-22 08:00AM
Sep-27-22 09:05AM
Sep-12-22 04:28PM
Aug-23-22 08:00AM
Aug-22-22 04:02PM
Aug-18-22 04:05PM
Aug-10-22 07:30AM
Aug-01-22 08:00AM
Jul-11-22 06:26AM
(Simply Wall St.) -14.71%
Jun-23-22 04:05PM
Jun-16-22 04:01PM
May-18-22 07:31AM
May-16-22 01:20PM
May-12-22 04:01PM
May-11-22 07:30AM
Apr-29-22 08:00AM
Apr-02-22 01:40PM
Mar-23-22 07:00AM
Mar-15-22 08:00AM
Feb-28-22 08:14AM
Feb-24-22 04:01PM
Feb-22-22 04:05PM
Feb-08-22 01:46PM
Feb-01-22 04:19AM
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sandford Nicole President & CEO Dec 06 '23 Buy 3.36 5,000 16,800 58,703 Dec 06 05:21 PM Merchant Minh Hoang Secretary & General Counsel Dec 06 '23 Sale 3.37 980 3,303 0 Dec 08 05:28 PM Hombeck Torsten Chief Financial Officer Sep 08 '23 Buy 4.30 2,246 9,658 3,000 Sep 12 06:37 PM SCHULER JACK W 10% Owner Jul 24 '23 Buy 2.75 181,800 499,950 1,883,656 Jul 25 05:39 PM Sandford Nicole President & CEO Jul 24 '23 Buy 3.98 12,563 50,001 134,665 Jul 25 05:16 PM Herchuk Jannie Prestridge Director Jul 24 '23 Buy 3.98 8,794 35,000 23,833 Jul 24 06:49 PM Parnell Winfred Director Jul 24 '23 Buy 3.98 6,281 24,998 31,513 Jul 25 05:03 PM Cavanaugh Stefanie L. Director Jul 24 '23 Buy 3.98 6,281 24,998 34,904 Jul 25 05:20 PM Jordan Veronica GH Director Jul 24 '23 Buy 3.98 3,769 15,001 34,575 Jul 24 06:58 PM Vos Ellen O'Connor Director Jul 24 '23 Buy 3.98 3,769 15,001 32,878 Jul 26 04:28 PM Merchant Minh Hoang General counsel and secretary Jul 24 '23 Buy 3.98 754 3,001 3,865 Jul 25 04:58 PM Fralick Celeste Rachelle Director Jul 24 '23 Buy 3.98 754 3,001 12,032 Jul 26 07:28 PM Hombeck Torsten Chief Financial Officer Jul 24 '23 Buy 3.98 754 3,001 754 Jul 24 06:53 PM Phan Ryan Thinh CSO & COO Jul 24 '23 Buy 3.98 628 2,499 3,939 Jul 25 05:11 PM
Index -
P/E -
EPS (ttm) -0.46
Insider Own 24.78%
Shs Outstand 81.90M
Perf Week -4.96%
Market Cap 58.45M
Forward P/E -
EPS next Y -0.24
Insider Trans 0.00%
Shs Float 62.30M
Perf Month -18.51%
Income -34.91M
PEG -
EPS next Q -0.10
Inst Own 9.40%
Short Float 0.58%
Perf Quarter -32.14%
Sales 0.80M
P/S 73.06
EPS this Y 28.40%
Inst Trans -0.74%
Short Ratio 1.82
Perf Half Y -8.35%
Book/sh -0.19
P/B -
EPS next Y 32.26%
ROA -186.28%
Short Interest 0.36M
Perf Year -54.47%
Cash/sh 0.14
P/C 4.97
EPS next 5Y -
ROE -5396.85%
52W Range 0.55 - 1.79
Perf YTD -1.58%
Dividend Est. -
P/FCF -
EPS past 5Y 2.75%
ROI -
52W High -60.58%
Beta 1.18
Dividend TTM -
Quick Ratio 0.43
Sales past 5Y 188.43%
Gross Margin -75.54%
52W Low 28.31%
ATR (14) 0.07
Dividend Ex-Date -
Current Ratio 0.43
EPS Y/Y TTM 16.93%
Oper. Margin -4432.36%
RSI (14) 45.09
Volatility 10.85% 9.92%
Employees 110
Debt/Eq -
Sales Y/Y TTM 133.06%
Profit Margin -4379.63%
Recom 1.50
Target Price 3.30
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 30.02%
Payout -
Rel Volume 0.31
Prev Close 0.68
Sales Surprise -70.91%
EPS Surprise 0.00%
Sales Q/Q 14.50%
Earnings May 14 BMO
Avg Volume 198.75K
Price 0.71
SMA20 -8.37%
SMA50 -6.72%
SMA200 -19.91%
Trades
Volume 61,383
Change 3.60%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-01-23 Downgrade
The Benchmark Company
Buy → Hold
Feb-17-22 Resumed
Cantor Fitzgerald
Overweight
$8 → $7
Mar-10-21 Initiated
Cantor Fitzgerald
Overweight
$8
May-16-18 Initiated
Maxim Group
Buy
$6
May-14-18 Reiterated
The Benchmark Company
Buy
$7 → $5
Sep-07-16 Reiterated
Rodman & Renshaw
Buy
$12 → $10
Feb-01-16 Initiated
Rodman & Renshaw
Buy
$12
May-29-24 08:00AM
May-15-24 03:01AM
May-13-24 05:11PM
(Associated Press Finance) +5.85%
04:10PM
May-08-24 08:00AM
08:00AM
Loading…
Apr-23-24 08:00AM
Mar-27-24 12:31PM
Mar-25-24 04:10PM
Mar-21-24 08:30AM
Mar-20-24 08:30AM
Mar-19-24 04:30PM
Feb-02-24 08:00AM
Jan-18-24 04:54AM
Jan-04-24 08:00AM
Dec-05-23 10:25AM
08:00AM
Loading…
08:00AM
Nov-16-23 09:15AM
Nov-15-23 05:08AM
(Associated Press Finance)
Nov-14-23 04:10PM
Nov-08-23 08:00AM
Nov-06-23 06:24AM
Nov-02-23 08:19AM
Oct-23-23 08:00AM
Oct-19-23 08:00AM
Oct-18-23 12:00PM
Oct-16-23 08:00AM
Oct-13-23 08:00AM
Oct-02-23 08:00AM
Sep-13-23 08:00AM
Aug-25-23 04:30AM
05:27PM
Loading…
Aug-14-23 05:27PM
(Associated Press Finance)
04:10PM
Aug-09-23 08:00AM
Jun-23-23 04:10PM
06:00AM
(Zacks Small Cap Research)
Jun-05-23 04:10PM
Jun-01-23 09:15AM
May-31-23 04:01PM
May-11-23 12:45PM
07:00AM
May-10-23 04:10PM
May-05-23 08:00AM
Apr-26-23 07:30AM
Apr-24-23 09:00AM
Mar-15-23 04:10PM
Mar-10-23 08:35AM
08:00AM
Mar-07-23 08:35AM
Mar-06-23 04:30PM
Feb-27-23 04:42AM
(Zacks Small Cap Research)
Feb-22-23 04:10PM
Feb-17-23 08:30AM
Feb-16-23 04:10PM
08:00AM
Jan-23-23 08:00AM
Jan-20-23 08:30AM
Jan-17-23 10:00AM
Jan-12-23 08:00AM
Jan-08-23 12:00PM
Dec-05-22 08:30AM
Nov-14-22 04:10PM
08:30AM
Nov-10-22 08:30AM
Nov-03-22 08:30AM
08:10AM
(Zacks Small Cap Research)
Oct-20-22 08:00AM
Oct-11-22 08:05AM
Oct-04-22 07:30AM
Sep-30-22 09:00AM
Sep-16-22 08:35AM
Sep-12-22 08:35AM
08:35AM
Aug-16-22 03:00PM
08:00AM
Aug-10-22 04:10PM
08:00AM
Aug-08-22 08:00AM
Aug-03-22 08:00AM
07:00AM
Aug-02-22 04:10PM
08:30AM
08:05AM
Jul-29-22 08:30AM
Jul-28-22 04:10PM
Jul-25-22 06:05AM
(Zacks Small Cap Research)
Jul-13-22 08:00AM
Jun-21-22 08:43AM
08:00AM
May-31-22 08:00AM
May-11-22 04:10PM
May-06-22 08:00AM
May-05-22 08:03AM
Apr-27-22 09:00AM
Apr-25-22 08:00AM
Apr-11-22 05:52AM
(Zacks Small Cap Research)
Apr-06-22 08:00AM
Mar-30-22 04:10PM
Mar-29-22 08:00AM
08:00AM
Mar-28-22 04:25PM
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Eight Corp Ltd 10% Owner Jan 02 '24 Sale 0.90 20,000 18,000 298,419 Jan 03 10:41 AM Butera Salvatore Thomas CEO - Volition Veterinary Dec 18 '23 Buy 0.83 10,000 8,300 99,350 Dec 19 10:59 AM Butera Salvatore Thomas CEO - Volition Veterinary Dec 15 '23 Buy 0.77 10,000 7,700 89,350 Dec 18 09:38 AM Eight Corp Ltd 10% Owner Dec 15 '23 Sale 0.75 20,000 15,000 318,419 Dec 20 10:31 AM Rootsaert Rodney Gerard Secretary Dec 13 '23 Buy 0.60 10,000 6,000 78,652 Dec 14 09:11 AM Reynolds Cameron John President and CEO Dec 08 '23 Buy 0.67 10,000 6,700 1,704,518 Dec 11 08:51 AM Innes Guy Archibald Director Nov 27 '23 Buy 0.77 20,000 15,400 627,161 Nov 28 09:39 AM Futcher Edward Director Nov 27 '23 Buy 0.80 9,000 7,200 71,936 Nov 28 09:39 AM Innes Guy Archibald Director Nov 24 '23 Buy 0.76 10,000 7,600 607,161 Nov 27 10:28 AM Innes Guy Archibald Director Nov 22 '23 Buy 0.71 20,000 14,200 597,161 Nov 24 11:06 AM Butera Salvatore Thomas CEO - Volition Veterinary Nov 16 '23 Buy 0.81 10,000 8,100 79,350 Nov 17 10:01 AM Barnes Phillip Director Sep 05 '23 Buy 1.30 5,000 6,500 24,686 Sep 06 10:01 AM Faulkes Martin Charles Director Aug 31 '23 Buy 1.28 9,716 12,436 1,673,532 Sep 01 09:41 AM Henshall Mickie Director Aug 31 '23 Buy 1.25 3,706 4,632 18,706 Sep 19 04:05 PM Micallef Jacob Vincent Chief Scientific Officer Aug 30 '23 Buy 1.27 8,750 11,112 55,000 Aug 31 09:35 AM Micallef Jacob Vincent Chief Scientific Officer Aug 29 '23 Buy 1.24 11,250 13,950 46,250 Aug 31 09:35 AM Micallef Jacob Vincent Chief Scientific Officer Aug 25 '23 Buy 1.24 20,000 24,800 235,140 Aug 28 10:07 AM Michel Gaetan Chief Operating Officer Aug 24 '23 Buy 1.23 5,000 6,150 212,997 Aug 24 12:00 PM Futcher Edward Director Aug 24 '23 Buy 1.22 5,000 6,100 62,936 Aug 25 11:49 AM Kway Jasmine CEO - Singapore Volition Aug 24 '23 Buy 1.20 5,000 6,000 10,400 Aug 25 11:49 AM Reynolds Cameron John President and CEO Aug 16 '23 Buy 1.22 10,000 12,200 1,494,518 Aug 16 12:28 PM Butera Salvatore Thomas CEO - Volition Veterinary Aug 16 '23 Buy 1.21 8,000 9,680 69,350 Aug 17 09:40 AM Butera Salvatore Thomas CEO - Volition Veterinary Jun 02 '23 Buy 1.59 10,000 15,900 61,350 Jun 06 10:14 AM
Index RUT
P/E -
EPS (ttm) -2.82
Insider Own 4.00%
Shs Outstand 89.90M
Perf Week -2.19%
Market Cap 2.06B
Forward P/E 102.29
EPS next Y 0.22
Insider Trans -6.80%
Shs Float 86.89M
Perf Month 16.90%
Income -234.60M
PEG -
EPS next Q -0.01
Inst Own 104.78%
Short Float 5.87%
Perf Quarter 2.61%
Sales 774.20M
P/S 2.66
EPS this Y 111.42%
Inst Trans 1.63%
Short Ratio 7.07
Perf Half Y 18.30%
Book/sh 8.40
P/B 2.71
EPS next Y 621.63%
ROA -20.58%
Short Interest 5.10M
Perf Year 3.17%
Cash/sh 1.15
P/C 19.75
EPS next 5Y -8.20%
ROE -29.41%
52W Range 13.82 - 25.95
Perf YTD 18.91%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -26.27%
52W High -12.29%
Beta 1.95
Dividend TTM -
Quick Ratio 1.82
Sales past 5Y 4.63%
Gross Margin 63.25%
52W Low 64.69%
ATR (14) 0.94
Dividend Ex-Date -
Current Ratio 1.99
EPS Y/Y TTM -56.54%
Oper. Margin -15.82%
RSI (14) 50.79
Volatility 3.34% 4.08%
Employees 2700
Debt/Eq 0.19
Sales Y/Y TTM 11.44%
Profit Margin -30.30%
Recom 2.69
Target Price 24.58
Option/Short Yes / Yes
LT Debt/Eq 0.17
EPS Q/Q 57.02%
Payout -
Rel Volume 0.83
Prev Close 22.46
Sales Surprise 4.49%
EPS Surprise 90.40%
Sales Q/Q 11.59%
Earnings May 07 AMC
Avg Volume 720.82K
Price 22.76
SMA20 -2.37%
SMA50 6.61%
SMA200 17.40%
Trades
Volume 595,531
Change 1.34%
Date
Action
Analyst
Rating Change
Price Target Change
May-08-24 Upgrade
Leerink Partners
Market Perform → Outperform
$25 → $35
Dec-21-23 Resumed
Piper Sandler
Neutral
$23
Dec-19-23 Initiated
Wells Fargo
Equal Weight
$20
Dec-14-23 Initiated
Guggenheim
Buy
$23
Dec-13-23 Initiated
Wolfe Research
Outperform
$28
Jul-05-23 Resumed
JP Morgan
Underweight
$18
May-23-23 Upgrade
Goldman
Sell → Buy
$18 → $25
Jan-18-23 Upgrade
Raymond James
Mkt Perform → Outperform
$25
Oct-06-22 Initiated
Stephens
Equal-Weight
$22
Oct-15-21 Resumed
Cowen
Market Perform
$33
Jun-15-21 Initiated
Raymond James
Mkt Perform
Jun-03-21 Initiated
Goldman
Sell
$25
Sep-26-19 Downgrade
BofA/Merrill
Neutral → Underperform
$30 → $28
Aug-14-19 Downgrade
Piper Jaffray
Overweight → Neutral
$45 → $40
Aug-02-19 Upgrade
BofA/Merrill
Underperform → Neutral
Aug-01-19 Upgrade
Barclays
Underweight → Equal Weight
$18 → $40
Jul-29-19 Downgrade
Needham
Strong Buy → Hold
Jul-09-19 Downgrade
Cowen
Outperform → Market Perform
Mar-12-19 Reiterated
Needham
Strong Buy
$37 → $41
Jan-03-19 Initiated
Needham
Strong Buy
$36
Show Previous Ratings
May-30-24 05:55PM
May-23-24 06:44PM
06:00PM
May-16-24 04:05PM
02:52AM
02:52AM
Loading…
02:52AM
May-13-24 09:45AM
May-10-24 06:00AM
May-09-24 06:55PM
(Morningstar Research) +5.43%
May-08-24 04:28PM
03:59PM
01:54PM
01:24PM
12:15PM
03:47AM
09:56PM
Loading…
May-07-24 09:56PM
07:00PM
06:02PM
05:50PM
04:47PM
(Associated Press Finance)
04:05PM
09:00AM
Apr-30-24 04:05PM
Apr-24-24 10:01AM
Apr-17-24 08:00AM
Apr-16-24 09:15AM
Apr-11-24 10:00AM
Apr-09-24 09:10AM
08:00AM
Mar-28-24 11:30AM
07:51AM
Loading…
Mar-27-24 07:51AM
Mar-21-24 09:40PM
Mar-20-24 04:05PM
Mar-01-24 09:41AM
Feb-28-24 02:45PM
(Morningstar Research) -8.04%
11:24AM
(Thomson Reuters StreetEvents)
10:24AM
07:50AM
Feb-27-24 07:00PM
06:30PM
04:42PM
04:05PM
09:15AM
Feb-26-24 09:16AM
Feb-21-24 04:05PM
Feb-16-24 07:05AM
Feb-15-24 04:05PM
Feb-01-24 09:25AM
Jan-30-24 05:00PM
Jan-25-24 07:05PM
Jan-22-24 08:55AM
Jan-18-24 06:10PM
Jan-09-24 04:05PM
Jan-04-24 11:10AM
Jan-03-24 04:05PM
Dec-21-23 03:05PM
09:17AM
08:30AM
Dec-20-23 08:00AM
Dec-14-23 08:22AM
Dec-06-23 11:30AM
Nov-21-23 10:54AM
Nov-20-23 04:05PM
11:18AM
Nov-16-23 04:05PM
Nov-09-23 07:00AM
Nov-08-23 09:20PM
04:10PM
Nov-07-23 02:30PM
(Morningstar Research) +8.69%
10:24AM
10:09AM
Nov-06-23 07:00PM
04:59PM
04:36PM
(Associated Press Finance)
04:05PM
Nov-04-23 03:02AM
Nov-03-23 07:04PM
(Morningstar Research) +6.51%
Nov-01-23 09:00AM
Oct-31-23 04:05PM
Oct-30-23 03:46PM
Oct-26-23 08:00AM
Oct-20-23 10:31AM
Oct-09-23 06:56PM
Sep-29-23 11:44AM
Sep-28-23 04:59PM
07:00AM
Sep-22-23 11:51AM
Sep-20-23 07:42AM
Sep-19-23 09:00AM
07:00AM
Sep-18-23 08:00AM
Sep-12-23 11:41AM
Sep-08-23 11:49AM
Sep-07-23 11:30AM
Sep-06-23 04:05PM
07:00AM
Sep-05-23 08:00AM
Aug-23-23 09:48AM
Aug-22-23 09:00AM
Aug-17-23 04:05PM
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DIAZ PAUL J President and CEO May 15 '24 Sale 25.07 75,000 1,880,415 1,066,166 May 15 05:49 PM DIAZ PAUL J President and CEO May 14 '24 Sale 25.21 95,000 2,394,798 1,141,166 May 15 05:49 PM DIAZ PAUL J President and CEO May 13 '24 Sale 25.13 57,844 1,453,550 1,236,166 May 15 05:49 PM Newcomer Lee Nisley Director May 13 '24 Sale 25.30 6,200 156,860 66,650 May 15 05:48 PM Riggsbee Richard Bryan Chief Financial Officer Dec 01 '23 Sale 19.09 30,000 572,835 291,812 Dec 05 04:19 PM Riggsbee Richard Bryan Chief Financial Officer Nov 01 '23 Sale 15.69 30,000 470,622 321,812 Nov 03 05:12 PM SPIEGELMAN DANIEL K Director Jun 02 '23 Sale 23.01 8,638 198,760 40,493 Jun 02 06:15 PM
Index -
P/E -
EPS (ttm) -0.82
Insider Own 17.75%
Shs Outstand 20.54M
Perf Week -1.04%
Market Cap 15.72M
Forward P/E -
EPS next Y -0.34
Insider Trans 0.00%
Shs Float 18.66M
Perf Month -0.76%
Income -11.51M
PEG -
EPS next Q -0.09
Inst Own 7.15%
Short Float 6.95%
Perf Quarter -60.64%
Sales 0.03M
P/S 523.91
EPS this Y 34.09%
Inst Trans -2.60%
Short Ratio 2.24
Perf Half Y -71.02%
Book/sh 0.14
P/B 4.93
EPS next Y 21.84%
ROA -178.70%
Short Interest 1.30M
Perf Year -53.51%
Cash/sh 0.07
P/C 10.08
EPS next 5Y -
ROE -356.34%
52W Range 0.17 - 3.56
Perf YTD -72.18%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -315.98%
52W High -80.54%
Beta 5.11
Dividend TTM -
Quick Ratio 3.78
Sales past 5Y 850.88%
Gross Margin -249.21%
52W Low 305.09%
ATR (14) 0.08
Dividend Ex-Date -
Current Ratio 3.78
EPS Y/Y TTM -41.48%
Oper. Margin -29392.23%
RSI (14) 39.00
Volatility 3.83% 11.82%
Employees 9
Debt/Eq 0.35
Sales Y/Y TTM -
Profit Margin -34879.52%
Recom 1.00
Target Price 4.67
Option/Short No / Yes
LT Debt/Eq 0.20
EPS Q/Q -82.53%
Payout -
Rel Volume 0.17
Prev Close 0.69
Sales Surprise -87.58%
EPS Surprise 14.84%
Sales Q/Q -
Earnings -
Avg Volume 578.92K
Price 0.69
SMA20 -7.54%
SMA50 -26.02%
SMA200 -43.02%
Trades
Volume 100,180
Change 0.83%
May-21-24 08:31AM
May-13-24 08:31AM
May-07-24 08:45AM
May-01-24 08:30AM
Apr-29-24 08:31AM
08:30AM
Loading…
Apr-24-24 08:30AM
Apr-12-24 08:45AM
Apr-09-24 08:31AM
Apr-04-24 08:31AM
Mar-14-24 08:31AM
Mar-05-24 08:31AM
Feb-15-24 08:46AM
Feb-07-24 08:31AM
Feb-05-24 08:31AM
Jan-24-24 08:31AM
08:31AM
Loading…
Jan-08-24 08:31AM
Jan-04-24 11:36AM
08:31AM
Jan-03-24 08:31AM
Jan-02-24 08:31AM
Dec-21-23 09:21AM
Dec-06-23 08:31AM
Dec-04-23 05:38PM
08:31AM
Nov-28-23 08:31AM
Nov-20-23 09:00AM
08:31AM
Nov-14-23 09:25AM
Nov-07-23 09:01AM
Oct-31-23 09:15AM
09:01AM
Loading…
09:01AM
Oct-17-23 09:01AM
Oct-12-23 08:30AM
Sep-20-23 09:01AM
Sep-07-23 09:01AM
Sep-06-23 09:16AM
Sep-05-23 09:01AM
Aug-18-23 08:30AM
Aug-02-23 08:30AM
Jul-26-23 01:30PM
Jul-06-23 09:05AM
Jun-21-23 08:45AM
Jun-13-23 09:01AM
May-16-23 10:35AM
May-10-23 09:01AM
May-04-23 08:30AM
Apr-26-23 08:30AM
Apr-12-23 08:30AM
Apr-05-23 08:30AM
Apr-03-23 06:15AM
Mar-31-23 06:30AM
Mar-29-23 09:27AM
Mar-08-23 04:15PM
09:27AM
Mar-02-23 08:00AM
Feb-28-23 08:00AM
Feb-22-23 08:01AM
Jan-05-23 08:00AM
Jan-04-23 04:15PM
Dec-28-22 08:00AM
Nov-21-22 08:00AM
Nov-17-22 07:01AM
Nov-16-22 04:15PM
Nov-14-22 08:13AM
Nov-08-22 07:12AM
Oct-26-22 08:30AM
Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercializes a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company was founded in 2007, and is headquartered in Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burton Paul Frederick Director Mar 31 '24 Option Exercise 1.42 8,803 12,500 8,803 Apr 08 03:28 PM Lau Stanley K. Director Mar 31 '24 Option Exercise 1.42 8,803 12,500 100,325 Apr 08 03:22 PM Intrater James Director Mar 31 '24 Option Exercise 1.42 8,803 12,500 71,596 Apr 08 03:07 PM Levy Oded Director Mar 31 '24 Option Exercise 1.42 8,803 12,500 71,596 Apr 08 02:59 PM Lau Stanley K. Director Jan 31 '24 Option Exercise 2.18 917 1,999 91,522 Feb 05 04:50 PM Lau Stanley K. Director Dec 31 '23 Option Exercise 2.49 6,626 16,499 90,605 Jan 02 05:40 PM Sim Brandon Director Dec 31 '23 Option Exercise 2.49 5,020 12,500 62,793 Jan 02 06:04 PM Intrater James Director Dec 31 '23 Option Exercise 2.49 5,020 12,500 62,793 Jan 02 05:58 PM Levy Oded Director Dec 31 '23 Option Exercise 2.49 5,020 12,500 62,793 Jan 02 05:49 PM Lau Stanley K. Director Oct 31 '23 Option Exercise 0.30 6,631 2,000 83,979 Nov 03 04:24 PM Lau Stanley K. Director Sep 30 '23 Option Exercise 0.34 42,647 14,500 77,348 Oct 04 12:15 PM Levy Oded Director Sep 30 '23 Option Exercise 0.34 36,765 12,500 57,773 Oct 03 06:01 PM Sim Brandon Director Sep 30 '23 Option Exercise 0.34 36,765 12,500 57,773 Oct 03 05:45 PM Intrater James Director Sep 30 '23 Option Exercise 0.34 36,765 12,500 57,773 Oct 03 05:53 PM Lau Stanley K. Director Aug 31 '23 Option Exercise 0.55 3,637 2,000 34,701 Oct 04 12:15 PM Dogan Timur Chief Technology Officer Aug 31 '23 Buy 0.55 16,481 8,982 128,345 Sep 08 12:12 PM Dogan Meeshanthini Chief Executive Officer Aug 31 '23 Buy 0.55 16,481 8,982 128,345 Sep 08 12:18 PM Philibert Robert Chief Medical Officer Aug 28 '23 Buy 0.60 18,000 10,795 1,649,792 Sep 05 04:14 PM Dogan Timur Chief Technology Officer Aug 25 '23 Buy 0.56 1,770 982 111,864 Sep 08 12:12 PM Dogan Meeshanthini Chief Executive Officer Aug 25 '23 Buy 0.56 1,770 982 111,864 Sep 08 12:18 PM Philibert Robert Chief Medical Officer Aug 24 '23 Buy 0.60 16,000 9,600 1,631,792 Sep 05 04:14 PM Lau Stanley K. Director Jul 31 '23 Option Exercise 1.21 1,653 2,000 31,064 Oct 04 12:15 PM Lau Stanley K. Director Jul 01 '23 Option Exercise 1.19 8,403 10,000 29,411 Jul 05 01:55 PM Lau Stanley K. Director Jun 30 '23 Option Exercise 1.19 21,008 25,000 21,008 Jul 05 01:55 PM Intrater James Director Jun 30 '23 Option Exercise 1.19 21,008 25,000 21,208 Jul 05 01:19 PM Sim Brandon Director Jun 30 '23 Option Exercise 1.19 21,008 25,000 21,008 Jul 05 01:13 PM Levy Oded Director Jun 30 '23 Option Exercise 1.19 21,008 25,000 21,008 Jul 05 01:04 PM
Index -
P/E -
EPS (ttm) -9.52
Insider Own 8.22%
Shs Outstand 2.31M
Perf Week -7.00%
Market Cap 4.30M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 2.12M
Perf Month -41.87%
Income -17.55M
PEG -
EPS next Q -
Inst Own 40.09%
Short Float 7.71%
Perf Quarter -44.14%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -78.38%
Short Ratio 0.69
Perf Half Y -78.47%
Book/sh 4.54
P/B 0.41
EPS next Y -
ROA -57.28%
Short Interest 0.16M
Perf Year -96.44%
Cash/sh 0.75
P/C 2.47
EPS next 5Y -
ROE -105.32%
52W Range 1.90 - 63.90
Perf YTD -76.03%
Dividend Est. -
P/FCF -
EPS past 5Y 67.29%
ROI -171.37%
52W High -97.09%
Beta 2.09
Dividend TTM -
Quick Ratio 0.62
Sales past 5Y -20.00%
Gross Margin -
52W Low -2.11%
ATR (14) 0.19
Dividend Ex-Date -
Current Ratio 0.62
EPS Y/Y TTM 2.71%
Oper. Margin 0.00%
RSI (14) 31.45
Volatility 6.69% 7.53%
Employees 6
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 32.00
Option/Short No / No
LT Debt/Eq 0.00
EPS Q/Q -308.10%
Payout -
Rel Volume 2.09
Prev Close 1.98
Sales Surprise -14.63%
EPS Surprise -79.41%
Sales Q/Q -
Earnings -
Avg Volume 237.87K
Price 1.86
SMA20 -22.58%
SMA50 -25.16%
SMA200 -79.59%
Trades
Volume 498,215
Change -6.06%
May-21-24 09:00AM
09:00AM
May-17-24 03:52PM
Apr-09-24 08:21AM
Mar-05-24 09:15AM
11:45AM
Loading…
Feb-13-24 11:45AM
Dec-29-23 12:45PM
Dec-06-23 09:15AM
Oct-19-23 09:00AM
Oct-04-23 07:30AM
Aug-14-23 08:30AM
Aug-02-23 08:30AM
Jul-31-23 09:00AM
Apr-12-23 08:30AM
Mar-20-23 08:55AM
08:30AM
Loading…
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Feb-28-23 08:30AM
Feb-21-23 08:45AM
Dec-06-22 09:40AM
Nov-17-22 08:00AM
Nov-14-22 08:00AM
Sep-20-22 08:00AM
Aug-30-22 08:30AM
Aug-03-22 09:45AM
Jul-29-22 09:19AM
Jul-26-22 07:30AM
Jul-12-22 09:30AM
Jun-21-22 10:30AM
Apr-05-22 09:15AM
09:26AM
Loading…
Mar-24-22 09:26AM
Feb-23-22 09:15AM
Feb-20-22 08:37AM
Feb-08-22 09:15AM
Feb-07-22 08:38PM
Jan-05-22 09:15AM
Dec-29-21 09:15AM
Dec-16-21 10:50AM
Dec-01-21 10:05AM
Nov-23-21 09:25AM
Nov-18-21 09:15AM
Nov-16-21 09:25AM
Nov-15-21 09:45AM
Oct-26-21 10:30AM
Oct-19-21 10:30AM
Oct-05-21 10:00AM
Sep-22-21 11:00AM
Sep-13-21 10:00AM
Sep-09-21 10:15AM
Aug-24-21 10:17AM
Aug-23-21 08:47AM
Aug-10-21 02:30PM
10:30AM
Aug-05-21 10:30AM
Jul-27-21 09:15AM
Jul-07-21 09:00AM
Jun-07-21 10:02AM
May-17-21 09:00AM
May-12-21 09:00AM
May-10-21 09:00AM
Apr-28-21 10:13AM
Apr-22-21 09:20AM
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rivard Paul Chief Legal Officer Aug 24 '23 Buy 1.11 150,000 166,500 400,000 Aug 24 05:58 PM Rivard Paul Chief Legal Officer Aug 17 '23 Buy 1.12 25,000 28,080 250,000 Aug 18 04:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite